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ABSTRACT
The clinical relevance of ischemia-reperfusion injury (IRI) in the context of organ
transplantation is well-established. IRI is associated with various forms of programmed cell
death (PCD), of which necroptosis is particularly significant. Necroptosis is an inflammatory
form of PCD that promotes alloimmunity and adversely affects allograft viability and function.
We have recently shown the role of cyclophilin D (CypD), a critical mediator of mitochondrial
permeability transition pore (mPTP) formation, in necroptosis. In this study, we investigated
the downstream mechanism of hypoxia/reoxygenation-induced necroptosis and the effect of
CypD inhibition in mitigating IRI-induced allograft injury and the subsequent alloimmune
response in a clinically relevant model of cardiac transplantation. Our data indicate that
inhibition of caspases during cold hypoxia-reoxygenation injury decreases apoptosis but
increases necroptosis and that inhibition of CypD attenuates hypoxia/reoxygenation-induced
necroptosis (n=3; p≤0.001). Interestingly, we found that hypoxia/reoxygenation-induced
necroptosis involves apoptosis-inducing factor (AIF) translocation to the nucleus and that AIF
silencing also attenuates hypoxia/reoxygenation-induced necroptosis (n=3; p≤0.001). Our in
vivo studies confirm that CypD deficiency in ischemia-treated donor hearts mitigates IRI and
allograft rejection (n=8; p=0.008). Our findings suggest that CypD inhibition following
transplantation substantially attenuates necroptosis and mitigates allograft injury and the
subsequent alloimmune response. Our data also indicate that AIF may be the downstream
effector molecule that executes IRI-induced DNA damage in necroptosis. As such, targeting
mitochondrial permeability may be a plausible approach in formulating therapeutic strategies
aimed at improving allograft viability and function.
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LAY SUMMARY
Organ transplantation is essential for patients with end-stage organ disease. However,
the procedure itself carries its own set of risks. One of the most pertinent risks is damage to the
donor organ after its blood supply is cut off. This type of injury is associated with cell death
and is called ischemic injury. It may be severe enough to render the donor organ unusable.
Despite stringent protocols and guidelines for organ procurement, preservation and
transportation, current strategies aimed at reducing ischemic injury are insufficient. Therefore,
targeting cell death pathways in ischemic injury may be a better approach. Before such
strategies can be developed, a thorough understanding of the cell death pathways in ischemic
injury is required. In this study, we investigated a type of cell death called necroptosis.
Necroptosis is a severe form of cell death that triggers the recipient's immune response against
the donor organ. Hence, inhibiting necroptosis can help prolong donor organ survival
following transplantation.
Although necroptosis is involved in ischemic injury, the precise cellular mechanism(s)
involved are not yet clear. According to recent research, a specialized cellular structure called
mitochondrion that generates the cells' energy may be involved in necroptosis. Our data from
this study indicate that mitochondrial components called 'Cyclophilin D' and 'ApoptosisInducing Factor' play essential roles in necroptosis. We used pharmacological agents and
genetic engineering techniques to inhibit the function of Cyclophilin D and ApoptosisInducing Factor in individual cells and found that it protects against ischemic injury. We then
extended our findings to an experiment simulating real-life conditions using mice hearts. We
found that inhibiting Cyclophilin D and Apoptosis-Inducing Factor provides protection against
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ischemic injury and helps promote donor heart survival. We hope to extend our findings to
clinical studies and believe that our research will make the organ transplantation process better.
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Chapter 1
INTRODUCTION
1.1 – Current Challenges in Cardiac Transplantation
Congestive heart failure (CHF) is a significant public healthcare burden and affects
37.7 million people worldwide [1, 2]. Common underlying causes of CHF include coronary
artery disease, valvular dysfunction, cardiac arrhythmias, cardiomyopathy and congenital heart
disease [1, 3]. The prevalence of CHF is predicted to rise further because of improvements in
the clinical management of CHF patients, an increase in predisposing conditions (diabetes,
hypertension), and population expansion and ageing [4, 5]. Despite marked improvements in
medical therapy and mechanical circulatory support devices, cardiac transplantation is the
preferred treatment option for unresponsive, end-stage CHF patients [6, 7, 8]. Compared to
end-stage CHF patients on optimal medical and device therapy, transplant recipients have
improved physical function, enhanced quality of life and prolonged survival [7, 8].
Advances in human leukocyte antigen (HLA) matching, biopsy procedures, surgical
techniques, and post-transplantation immunosuppressive protocols have increased the 1-year
survival rate of patients undergoing cardiac transplantation to ~90% [7, 8, 9]. However, various
limitations and challenges still exist. Postoperative management of patients undergoing cardiac
transplantation is challenging. It includes monitoring for and addressing numerous
complications with potentially significant impact on patient morbidity and mortality. These
include graft failure/dysfunction (primary and late), allograft rejection, cardiac allograft
vasculopathy, and adverse effects related to chronic immunosuppressive drugs (malignancy,
infection) [7, 8, 10]. Despite the marked improvement in the 1-year survival rates,
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complications related to chronic immunosuppression, chronic rejection and late graft failure
are significant obstacles to long-term survival [7, 8, 10, 11]. Currently, the successful
management of these significant post-transplantation complications is limited, and a thorough
understanding of these conditions needs to be developed for improving long-term graft survival
and function [7, 8, 10].

1.2 – Ischemia-Reperfusion Injury in Organ Transplantation
Ischemia-reperfusion injury (IRI) is an inevitable consequence of organ transplant
procedure (Figure 1) that can have life-threatening consequences in the immediate
postoperative period, such as primary graft failure or dysfunction. IRI has also been shown to
have deleterious long-term effects on graft survival and can contribute to graft rejection (Figure
3) [4, 8, 12].
1.2.1 – Pathophysiology of Ischemia Injury – Ischemia occurs with the cessation of arterial
blood flow during organ procurement. It is a period of insufficient oxygen and nutrients supply
that disrupts the electron transport chain (ETC) and oxidative phosphorylation, which induces
anaerobic metabolism [13, 14]. This ultimately leads to the depletion of adenosine triphosphate
(ATP) and profoundly affects cellular homeostasis. Failure of ATP-dependent membrane
pumps such as the Na+/K+ ATPase pump leads to intracellular sodium overload, causing
cellular edema, followed by cell swelling and altered ionic composition [13, 15]. Potassium
ions move out of the cell while calcium ions accumulate within the cytoplasm due to reduced
extracellular efflux by Ca2+ pumps and limited uptake by the endoplasmic reticulum (ER). The
accumulation of intracellular calcium activates calcium-dependent proteases (e.g., calpains)
and phospholipases, which results in injury to various cellular components [13, 14, 15, 16].
Anaerobic metabolism leads to lactic acid accumulation, intracellular acidosis and decreased
2

activity of many cellular enzymes. ATP depletion and cellular edema also result in detachment
of the ribosomes from the rough ER (RER) and disruption of the cell’s protein-synthesizing
machinery [13, 14, 15, 17]. Ionic and metabolic alterations can be reversed; however, once
there is damage to the plasma membrane, lysosomes and mitochondria, irreversible widespread
cellular injury occurs, and cell death follows (Figure 2) [13, 18].
1.2.2 – Pathophysiology of Reperfusion Injury – Although the restoration of blood is
imperative to limit the degree of ischemic injury, it can have detrimental consequences. Injury
induced by the restoration of blood supply is called reperfusion injury and occurs following
reimplantation of the donor organ into the recipient. Reperfusion injury can damage previously
unaffected cells and exacerbate injury caused by ischemia [13, 18]. Due to dysfunctional ETC
activity and impaired cellular/mitochondrial enzymes, incoming oxygen is incompletely
reduced and results in the generation of reactive oxygen species (ROS) [13, 14, 17]. ROS
contribute to oxidative stress and avidly attack many biological molecules, including proteins,
lipids, and nucleic acids [13, 17, 18, 19]. ROS-mediated cellular damage is exacerbated by the
reduced antioxidant and ROS scavenging capacity of the cell. Restoration of blood flow further
increases the intracellular accumulation of calcium ions transiently. The excess calcium ions
are transported into the mitochondrial matrix by the mitochondrial Ca2+ uniporter [13, 17, 18].
Along with ROS, the excess calcium may induce the formation of the mitochondrial
permeability transition pore (mPTP), which disrupts the proton motive force (PMF) and the
mitochondrial transmembrane potential (ΔΨm) causing further depletion of ATP [13, 17, 20].
mPTP formation also leads to augmented osmotic pressure within the mitochondria, followed
by mitochondrial swelling and rupture, releasing various mediators involved in cell death
pathways (Figure 2) [13, 20].

3

1.2.3 – IRI-Associated Inflammatory Response – The pathological changes induced by IRI
trigger a non-specific inflammatory response that contributes to the immunogenicity of the
allograft and adversely affects allograft survival and function [21, 22]. This inflammatory
response is initiated and perpetuated by ROS-mediated cell damage that alters several
endogenous molecules. The altered molecules are called damage-associated molecular patterns
(DAMPs) and include extracellular ATP, DNA fragments, uric acid (DNA breakdown
product), heat shock proteins, heparan sulphate, and many others [21, 23, 26]. DAMPs are
recognized by cellular pattern recognition receptors (PRRs) present on circulating leukocytes,
endothelial cells, and epithelial cells [21, 26]. Ligation of PRRs activates the cytoplasmic
protein called NLR Family Pyrin Domain Containing 3 (NLRP3), which in turn assembles a
multiprotein cytosolic complex called the inflammasome. The inflammasome recruits and
activates caspase-1, which processes various proinflammatory cytokines, including potent
inflammatory mediators such as interleukins-1β (IL-1β) and -18 (IL-18) [21, 24, 25]. The
engagement of PRRs, particularly toll-like receptors 2 and 4 (TLR-2 and 4), by DAMPs also
activates nuclear factor-kappa B (NF-κB), a transcription factor that translocates to the nucleus
and upregulates the expression of several proinflammatory cytokines and chemokines [21, 26].
The important upregulated proinflammatory cytokines include tumor necrosis factor-alpha
(TNFα), interferon-gamma (IFNγ), IL-1, and IL-6, while the important chemokines include
IL-8 and monocyte chemoattractant protein 1 (MCP-1). These chemokines belong to the C-XC (e.g., IL-8) and C-C chemokine (e.g., MCP-1) groups and are secreted by leukocytes and
endothelial cells. The expression of proinflammatory cytokines and chemokine signaling
promotes leukocyte infiltration and the activation of the complement system, thereby initiating
the innate immune response [21, 26, 27].
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All cells of the innate immune system express PRRs and are capable of sensing
DAMPs; however, neutrophils and monocytes are principally responsible for acute
inflammatory injury associated with IRI [21, 28, 29]. Neutrophils are the first leukocytes to
infiltrate the site of injury. DAMPs and IL-8 from resident tissue macrophages, dendritic cells,
and endothelial cells serve as potent neutrophil chemokines [21, 28]. Neutrophil-mediated graft
injury involves the production and release of proteases, hydrolytic enzymes, neutrophil
extracellular traps (NETs), and ROS [21, 30]. Moreover, in the presence of TNFα, neutrophils
release various proinflammatory cytokines and chemokines that recruit additional leukocytes,
including monocytes [21, 28]. Once recruited to the site of injury, monocytes differentiate into
macrophages and can undergo the proinflammatory M1 or the anti-inflammatory M2
polarization. TNFα and IFNγ stimulation and engagement of macrophage PRRs, particularly
TLR2 and TLR4, by DAMPs promote M1 polarization [21, 31, 32, 33, 34]. Activated M1
macrophages produce ROS and several proinflammatory cytokines like IL-1, IL-6, IL-17, IL23, TNFα, and IFNγ that mediate graft injury via diverse pathways, including the induction of
programmed cell death pathways [35, 36, 37, 38, 39]. Macrophage recruitment also results in
significant injury to the microvasculature and activation of the adaptive alloimmune responses
[21, 31, 32]. Natural Killer (NK) cells have also been shown to play crucial roles in mediating
acute and chronic allograft injury. Several studies have shown that NK cells are capable of
'directly' lysing allograft endothelial and epithelial cells [40, 41]. NK cells can also 'indirectly'
induce cellular death in the allograft by enhancing cellular and humoral alloimmune responses.
NK cell-mediated allograft injury is significant and can occur even in the presence of T cell
tolerance but remains an overlooked aspect of the immunosuppressive therapeutic strategies
aimed at inducing allograft tolerance [40, 41, 42, 43, 44].
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1.2.4 – Role of Endothelial Cells in IRI and Associated Inflammatory Response – Endothelial
cells play a crucial role in the inflammatory response associated with IRI. Leukocyte
recruitment at the site of injury involves ‘endothelial activation’ – a process that induces a
series of changes in the endothelial cells that facilitate their interaction with leukocytes [45,
46]. TNFα, IL-1, and IL-6 upregulate the expression of adhesion molecules on the surface of
endothelial cells via the activation of the NF-κB pathway [46, 47, 48]. The upregulated
adhesion molecules include selectins (e.g., E-selectin and P-selectin), intercellular adhesion
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). Surface
glycoproteins on activated leukocytes called integrins [e.g., leukocyte function-associated
antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1)] serve as ligands for endothelial cell
adhesion molecules and mediate leukocyte adhesion to the endothelium. This is followed by
leukocyte transmigration through the endothelium, which is aided by the adhesion molecule
platelet endothelial cell adhesion molecule-1 (PECAM-1), and infiltration into the graft tissue
along a chemokine gradient [21, 45, 46, 47, 48, 49].
Endothelial activation can lead to ‘endothelial dysfunction’ if the inflammatory injury
associated with IRI is severe, as is the case with prolonged ischemia times, inefficient organ
preservation, or the use of extended-criteria donor organs. Severe inflammation leads to
endothelial cell injury and impaired vascular homeostasis due to uncontrolled ROS production,
and persistently elevated levels of proinflammatory cytokines, especially TNFα. The central
mechanism underlying endothelial dysfunction is decreased nitric oxide (NO) bioavailability
due to inhibition of endothelial nitric oxide synthase (eNOS) [46, 50, 51, 52]. Under normal
physiological conditions, NO maintains vasodilation, suppresses platelet aggregation, prevents
leukocyte adhesion, attenuates vascular smooth muscle cell proliferation, and inhibits the
expression of proinflammatory cytokines (via downregulation of the NF-κB pathway) [46, 53,
6

54, 55]. Thus, the inhibition of eNOS due to oxidative stress and endothelial cell injury/death
promotes vasoconstriction and leads to a pro-thrombotic and proinflammatory state [49, 50,
51, 52, 53, 54, 55]. Furthermore, oxidative depletion of eNOS cofactor, tetrahydrobiopterin
(BH4), in dysfunctional endothelial cells ‘uncouples’ eNOS resulting in the incomplete
reduction of molecular oxygen and generation of more ROS [49, 56]. Finally, endothelial cell
injury/death results in the loss of vascular integrity and increased vascular permeability
facilitating leukocyte infiltration into graft tissue and the generation of an alloimmune response
[21, 49, 50, 51].
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Figure 1 – Ischemia-Reperfusion Injury During Organ Transplantation
In the transplant setting, ischemia occurs in two phases called the 'warm ischemia phase' and
the 'cold ischemia phase.' Warm ischemia occurs when the blood supply of the donor organ is
interrupted and lasts until the donor organ is flushed with a cold organ preservation solution.
Cold ischemia occurs during organ preservation. Currently, the most common method of donor
organ preservation is static cold (4°C) storage on ice. The donor organ undergoes another brief
period of warm ischemia when it is removed from cold storage until blood flow to the graft is
re-established [57, 58, 59].
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Figure 2 – Cellular Biology of Ischemia-Reperfusion Injury
The most important biochemical abnormality in ischemic cells is the decreased intracellular
generation of ATP. Loss of ATP leads to the failure of many energy-dependent cellular
systems, including ATP-dependent ion pumps, which results in increased intracellular sodium
and calcium. Anaerobic glycolysis leads to lactic acid accumulation, resulting in intracellular
acidosis. Ultimately, the failure of the critical energy-dependent systems and altered cellular
ionic homeostasis can lead to cell death. During reperfusion, there is increased generation of
ROS due to impaired cellular/mitochondrial enzymes, dysfunctional ETC components and
reduced cellular ROS-scavenging capacity. The ROS that are generated cause damage to lipids,
proteins and DNA and along with increased intracellular calcium induce mPTP formation.
mPTP formation leads to loss of PMF, as a result of which there is a further decline in ATP

9

production. mPTP formation also leads to the release of mitochondrial factors involved in PCD
pathways [13, 18, 20].
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1.3 – Cardiac Allograft Dysfunction and Rejection
The cumulative pathological changes induced by IRI and the subsequent inflammatory
response have a detrimental impact on the outcome of cardiac transplantation. IRI contributes
to alloimmune injury and influences short-term as well as long-term allograft survival and
function (Figure 3) [8, 10, 11, 12].
1.3.1 – Primary Graft Dysfunction – Amongst the early complications, primary graft
dysfunction (PGD) remains the leading cause of mortality in heart transplant recipients, with
a 30-day mortality rate of ~30% [8, 60]. PGD presents as the failure of the graft to meet the
circulatory requirements of the recipient due to ventricular dysfunction and develops within 24
hours of transplantation. Although PGD is not associated with a discernible cause, numerous
studies have postulated IRI as the predominant factor in its development [8, 59, 60, 61].
1.3.2 – Cardiac Allograft Rejection – The inflammatory insult associated with IRI promotes
leukocyte recruitment (via endothelial adhesion molecules) and activation (via expression of
proinflammatory cytokines/chemokines and release of cDAMPS). Leukocyte infiltration into
the cardiac allograft perpetuates graft injury and initiates alloimmune responses, which
culminates in allograft transplant rejection. Although the development of novel and effective
immunosuppressive agents has significantly reduced the rejection rates, it continues to remain
one of the major causes of death after cardiac transplantation [8, 10, 62]. Rejection can be
classified as hyperacute, acute cellular (cell-mediated) or humoral (antibody-mediated)
rejection [8, 10].
1.3.3 – Hyperacute Rejection – Hyperacute rejection occurs within minutes to hours following
transplantation and manifests as severe graft failure with hemodynamic instability. It is
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mediated by pre-formed antibodies directed against antigens in the cardiac allograft. The target
antigens include human leukocyte antigens (HLA) and ABO blood antigens expressed on the
allograft endothelial cells. The binding of the alloantibodies to these antigens activates the
complement system, which results in endothelial disruption, thrombosis, hemorrhage, and
irreversible rapid destruction of the graft by the recipient’s immune system [8, 63, 64].
Histologically, hyperacute rejection manifests as vasculitis and ischemic necrosis of the
cardiac allograft due to occlusive thrombosis. The management of hyperacute rejection is
complicated and involves pharmacological and mechanical circulatory support, along with
intense immunosuppression and plasmapheresis to remove the circulating alloantibodies.
Hyperacute rejection has a high mortality rate but is now uncommon due to comprehensive
pre-transplant cross-match testing, including panel-reactive antibody (PRA) screening [8, 63,
64, 65].
1.3.4 – Acute Cellular Rejection – Acute cellular rejection (ACR) is the most common type
of rejection after cardiac transplantation, with over 60% of the patients experiencing one or
more episodes [8, 62, 68, 69]. It generally occurs within the first six months posttransplantation [8, 62, 69]. ACR involves coordination between the innate and the adaptive
immune systems, with T cells playing a central role [8, 69, 70, 71]. Alloantigen recognition in
ACR can occur via the direct or the indirect pathways. In the direct pathway of alloantigen
recognition, recipient T cells recognize 'intact' non-self major histocompatibility complex
(MHC) molecules on donor cells within the graft tissue. In the indirect pathway, 'processed'
non-self MHC molecules are presented by recipient MHC molecules to recipient T cells [70,
71, 72]. Of the professional antigen presenting cells (APCs), dendritic cells play the most
important role in eliciting the alloimmune response by capturing and presenting antigens to the
naive T cells in lymph nodes. The resulting primed T cells then migrate to, infiltrate, and attack
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the graft tissue by multiple mechanisms, including lysis of graft cells, alloantibody production,
complement activation, and recruitment of monocytes and macrophages [70, 72]. Various
cytokines orchestrate the ACR response, the most important of which are TNFα, IL-1β, and
CD40 [70, 73, 74, 75, 76]. Both CD4+ helper and CD8+ cytotoxic T cells are implicated in
ACR [8, 69, 70, 71, 72]. Histologically, ACR is characterized by leukocyte infiltration with a
predominance of T cells, edema, hemorrhage, myocyte damage/necrosis, and vasculitis [8, 69,
71]. The incidence and management of ACR have significantly improved in the past few
decades due to advancements in biopsy techniques, improved histopathological grading
systems, and the development of potent immunosuppressive agents [8, 66, 67].
1.3.5 – Antibody-Mediated Rejection – Antibody-mediated rejection (AMR) typically occurs
within the first few months following cardiac transplantation in 10-20% of the patients [77, 78,
79]. Recipient antibodies directed against MHC Class I and Class II molecules on the surface
of endothelial cells, activate the complement system, and initiate inflammatory pathways that
cause injury to graft tissue [8, 77, 78, 79]. The recipient alloantibodies may be pre-formed and
present prior to transplantation or may form following innate immune system activation after
transplantation. Complement activation leads to endothelial cell and myocyte lysis via the
formation of membrane attack complex (MAC) [66, 79, 80]. Since the primary focus of the
recipient alloantibodies is the endothelium, the allograft microvasculature undergoes
significant injury resulting in increased vascular permeability and intravascular thrombosis.
The complement fragments C3a and C5a induce endothelial activation, and serve as potent
chemokines for neutrophils and macrophages, which further augments the inflammatory injury
through cytotoxic actions, ROS production and cytokine release [8, 77, 78, 79].
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Histologically, AMR was initially described as a "biopsy-negative rejection" due to
vasculitis, edema and hemorrhage in the absence of cellular infiltrate in the graft tissue;
however, standardized clinical and pathological criteria for the diagnosis of AMR are now
available [71, 77, 78, 79]. Myocardial capillaries, venules and arterioles display varying levels
of injury depending on the severity of AMR, with vasculitis and leukocyte infiltration
indicating an active AMR response. Interstitial edema, hemorrhage and intravascular thrombi
may also be seen. AMR necessitates aggressive immunosuppression with more severe cases
requiring plasmapheresis and hemodynamic support. Severe or persistent AMR may lead to
cardiac allograft vasculopathy [8, 71, 77, 78, 79, 81, 82].
1.3.6 – Cardiac Allograft Vasculopathy – Cardiac allograft vasculopathy (CAV) represents a
substantial barrier to the long-term survival of the cardiac allograft. It is the most significant
determinant of patient survival after three years of cardiac transplantation and occurs in up to
50% of the patients within ten years of the transplant procedure [8, 65, 83, 84, 85]. CAV is
characterized by progressive diffuse concentric intimal hyperplasia and medial disease
involving the epicardial and intramural arteries, arterioles, and capillaries with relative sparing
of the venules and veins [71, 83, 85, 86]. The pathophysiologic factors involved in the
development of CAV are both immunologic and non-immunologic. Immunologic factors
include the degree of MHC mismatch between the donor and the recipient, and the severity of
the acute rejection episodes, particularly those involving injury to the endothelium (such as
AMR) [71, 83, 85]. Non-immunologic factors include age, sex, obesity, dyslipidemia, diabetes
mellitus, hypertension, and graft IRI [66, 67, 83, 85]. Both immunologic and non-immunologic
factors result in endothelial activation/dysfunction [8, 66, 67, 83, 85].

14

MHC molecules on the surface of graft endothelial cells activate recipient CD4+ helper
and CD8+ cytotoxic T cells, which then orchestrate the graft injury and fibroproliferative repair
processes by recruiting inflammatory cells and inducing cytokine secretion [83, 85, 86, 87].
The important cytokines include IL-2, TNFα, and IFNγ. IL-2 promotes T cell proliferation and
differentiation while TNFα and IFNγ both increase the expression of MHC molecules and
promote endothelial activation/dysfunction [83, 85, 87, 88, 89]. TNFα also has direct cytotoxic
effects and IFNγ activates macrophages. The recruited macrophages contribute to graft injury
and produce several growth factors such as platelet-derived growth factor (PDGF), insulin-like
growth factor-1 (IGF-1) and transforming growth factors α and β (TGFα and β) [83, 88, 89].
These growth factors cause smooth muscle cell migration, proliferation, and extracellular
matrix deposition in the intima, resulting in concentric thickening of the vasculature [8, 66, 67,
83, 85, 86, 87, 88, 89, 90].
Clinically, CAV is asymptomatic due to denervation of the transplanted graft and is
difficult to detect. It is a progressive disease associated with adverse outcomes and may
necessitate surgical intervention for revascularization and re-transplantation in the most severe
cases. Furthermore, the current surveillance methods and diagnostic tools for the detection of
CAV have significant limitations. Accordingly, prevention is an essential strategy [8, 83, 85,
88, 91]. The use of statins and mammalian target of rapamycin (mTOR) inhibitors provide
significant protection against CAV [8, 83, 91, 92]. Addressing the immunologic and nonimmunologic factors associated with the development of CAV is also important [8, 66, 83].
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Figure 3 – Clinical Consequences of Ischemia-Reperfusion Injury in Organ
Transplantation
The cumulative pathological changes induced by IRI causes cellular death and inflammation
with life-threatening consequences in the immediate postoperative period, such as primary
graft dysfunction/non-function. IRI contributes to acute and chronic alloimmune injury via
cellular and humoral immune responses and has been shown to have deleterious long-term
effects on graft survival and contributes to graft rejection. The use of potent
immunosuppressive agents to induce graft tolerance is also associated with life-threatening
adverse effects such as diabetes, infections and malignancy [8, 10, 12, 65, 66, 67, 77, 90].
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1.4 – The Endothelium in Cardiac Transplantation
The endothelium is crucial in maintaining the vascular homeostasis by regulating
thrombosis, thrombolysis, platelet adherence, vascular tone, and blood flow. It also plays an
active part in immune surveillance by facilitating and limiting the recruitment of leukocytes
and stimulating immune reactivity. In transplantation, it represents the first barrier between the
graft tissue and the recipient's immune system. The role of the endothelium on the outcome of
the transplantation procedure was often overlooked in the past [42, 93, 94]. This was
particularly true for cardiac transplantation, where cardiomyocytes were considered more
sensitive to IRI and the primary target of the alloimmune response. Several studies have now
established that endothelial cells are not only more susceptible to IRI than cardiomyocytes but
also perpetuate the graft IRI and play an active role in the subsequent alloimmune response
[95, 96].
Endothelial cells undergo many of the pathological changes associated with IRI,
including disruption of critical energy-dependent cellular systems, intracellular acidosis,
electrolyte imbalances, cellular swelling, and damage to various biological molecules by ROS
and degradative enzymes [49, 94, 95]. These changes can induce endothelial
activation/dysfunction, injury, and death. Endothelial activation/dysfunction contributes to the
inflammatory response associated with IRI by secreting proinflammatory cytokines (IL-1, IL6, IL-8, TNFα) and upregulating the expression of adhesion molecules (E-selectin, P-selectin,
ICAM-1, VCAM-1) that facilitate leukocyte infiltration into the graft tissue [50, 51, 94]. Injury
to the endothelial cells generates ROS and cDAMPS that perpetuate IRI and augment the
inflammatory response [47, 48, 49, 50, 56]. Endothelial cells express many alloantigens and
contribute to the development of alloimmune responses [8, 10, 65, 66, 67, 77, 90]. They also
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express MHC molecules (Class I and II) and co-stimulatory molecules, including CD80 and
CD86, that can activate naive T cells [97, 98, 99, 100]. Endothelial cells are the primary target
in all types of graft rejection [8, 72, 77, 83, 94]. In the chronic setting, they play a crucial role
in allograft vascular disease by stimulating the migration of smooth muscle cells to the intimal
layer and deposition of fibrous matrix. Significant endothelial cell injury and death results in
loss of vascular integrity and tone, increased vascular permeability, and intravascular
thromboses, which disrupts blood flow, promotes inflammation and alloimmunity, and
ultimately, contributes to graft injury and necrosis [8, 10, 65, 66, 67, 77, 90].

1.5 – Endothelial Cell Death
At the cellular level, the cumulative pathological changes induced by IRI may lead to
cell death, which may be unregulated or programmed (Figure 2) [101, 102, 105]. The
detrimental effects of cell death on graft injury and alloimmunity have been extensively
characterized. Inhibiting cell death in organ transplantation is important for two reasons.
Firstly, uncontrolled cell death with insufficient replacement of cells adversely affects graft
survival and function [102, 103, 104, 105]. Secondly, the release of cytoplasmic contents and
cDAMPs from dying cells triggers and sustains alloimmune responses [13, 18, 20, 21]. Several
different forms of programmed cell death (PCD) are now known, broadly classified as
apoptosis and regulated necrosis types. The latter includes many further types, including
necroptosis, pyroptosis, ferroptosis, and oxytosis, among others. [101, 102, 105]. As the role
of these different forms of PCD in organ transplantation becomes increasingly evident,
targeting these cell death pathways can potentially present novel therapeutic approaches to
preserve graft function and survival. This is especially important considering the limited
success of recipient immunosuppression in alleviating alloimmunity and prolonging graft
18

survival. Amongst the various regulated necrosis types, the detrimental role of necroptosis in
inducing graft injury and alloimmunity is best characterized [102, 103, 104, 105].
Endothelial cells are susceptible to the different forms of PCD induced by IRI (Figure
4). Given the central role of the endothelium in developing and sustaining the alloimmune
response, preventing endothelial cell death is particularly important. Several studies, including
some from our group, have established the role of apoptosis and necroptosis in cardiac and
other solid organ transplantation [8, 10, 25, 26, 27, 28, 32, 43, 44]. Understanding the mediators
and the signal transduction pathways involved in the induction of endothelial cell necroptosis
will help elucidate targets for mechanism-based inhibitors that can help preserve graft survival
and function [102, 103, 104, 105].
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Figure 4 – Programmed Cell Death Pathways Induced by Ischemia-Reperfusion Injury
In the context of IRI, the major PCD pathways studied include apoptosis, necroptosis and
parthanatos. The mitochondria play a critical role in inducing all of the PCD pathways
associated with IRI. Although the downstream mechanisms involved in necroptosis are not
established, most studies strongly support a role for the mitochondria in necroptosis and
suggest the involvement of the CypD-mediated mPTP formation [13, 102, 105, 106, 107].
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1.6 – Necroptosis
1.6.1 – Shared Upstream Pathway of Apoptosis and Necroptosis – The upstream signaling
pathways of apoptosis (extrinsic) and necroptosis are shared (Figure 5). In organ
transplantation, apoptosis and necroptosis can both be initiated due to direct and severe injury
to the cell or due to proinflammatory cytokines and factors. The ligation of TNFα with TNFreceptor 1 (TNF-R1) mediates the best characterized pathway of necroptosis. Necroptosis can
also be initiated by TLR3, TLR4, Fas ligand, and TNF-related apoptosis-inducing ligand
(TRAIL) [102, 103, 104, 105, 106]. IRI involves the expression of several of these factors as
well as necroptosis-inducing injury to the cells such as ROS-mediated damage and calcium
overload [13, 18, 20].
The binding of TNFα to TNF-R1 recruits TNF receptor-associated death domain
protein (TRADD), TNF-receptor associated factors 2 and 5 (TRAF2/5), cellular inhibitors of
apoptosis 1 and 2 (cIAP1/2), linear ubiquitin chain assembly complex (LUBAC), and receptorinteracting serine/threonine protein kinase 1 (RIPK1). This complex of proteins is called
‘Complex I.’ cIAP1/2, and LUBAC possess E3 ubiquitin ligase activity and polyubiquitinate
RIPK1. This results in signaling through the pro-survival NF-κB pathway and counters the
cytotoxic effects of TNFα [102, 103, 104, 105, 106].
In the presence of persistent or severe injury, RIPK1 is deubiquitinated by the enzymes
A20 and cylindromatosis (CYLD). CYLD is a deubiquitinase that counters the ubiquitin ligase
activities of cIAP1/2 and LUBAC and removes the ubiquitin chains from RIPK1.
Deubiquitinated RIPK1 dissociates from Complex I and interacts with FAS-associated Death
Domain (FADD), procaspase-8 and cellular FLICE-like inhibitory protein (c-FLIP) to form
the ‘Death Inducing Signaling Complex’ (DISC) or ‘Complex IIa.’ c-FLIP has three different
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splice variants, c-FLIPL, c-FLIPS and c-FLIPR, which regulate the activity of caspase-8
differently. c-FLIPS and c-FLIPR inhibit apoptosis by preventing caspase-8 processing and
activation. c-FLIPL is an enzymatically inert homolog of caspase-8 and its activity is dependent
on its expression levels, which in turn is dependent on the extent of cellular injury and the level
of NF-κB activation [102, 105, 108].
When expressed at low levels, c-FLIPL forms a heterodimer with procaspase-8 and
activates it. Activated caspase-8 is considered the ‘initiator’ caspase. It forms homodimers that
activate the procaspases-3, -6 and -7 to their ‘effector’ active forms, which mediate cell death
via apoptosis. The c-FLIPL/caspase-8 heterodimer prevents necroptosis by cleaving the crucial
necroptotic mediators RIPK1 and RIPK3. The inhibitory effect of c-FLIPL/caspase-8
heterodimer on necroptosis explains why caspase-8 deficient mice are embryonically lethal
and why RIPK3 deficiency in these mice rescues them from lethality [102, 107, 108]. This also
indicates that, in addition to promoting apoptosis, an important function of caspase-8 is to
prevent necroptosis. When expressed at high levels, c-FLIPL partially processes procaspase-8,
the cleavage activity of which is limited to DISC. This partially processed caspase-8 cleaves
the DISC associated proteins, including RIPK1 and itself, and prevents both apoptosis and
necroptosis [102, 103, 104, 107, 108].
It is important to note that the ubiquitination status of RIPK1 determines cellular fate.
RIPK1 ubiquitination promotes cellular survival by restricting the interactions of the proapoptotic caspase-8 and the pro-necroptotic RIPK3 with RIPK1. Deubiquitination of RIPK1
promotes cell death by permitting the interaction of caspase-8 and RIPK3 with RIPK1 and
activating the downstream death pathways [102, 105, 106, 107, 108].
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1.6.2 – The ‘Necrosome’ – If caspase-8 activity is disrupted (in case of mutation, inhibitory
viral proteins or ischemia), RIPK1 detaches from DISC and interacts with RIPK3 via the RIP
homotypic interaction motif (RHIM) domains. RIPK1 and RIPK3 then auto- and transphosphorylate each other to form the 'necrosome' or 'Complex IIb.' The necrosome-associated,
phosphorylated RIPK3 then phosphorylates mixed lineage kinase domain-like protein
(MLKL), which initiates the downstream signaling in necroptosis. When overexpressed,
RIPK3 can also phosphorylate MLKL independent of RIPK1 [102, 105, 106, 109, 110].
1.6.3 – Downstream Pathway of Necroptosis – It is now established that necrosome formation
and phosphorylation of MLKL are essential for necroptosis; however, the precise pathway
downstream of necrosome formation is unclear. Several studies have been conducted to
elucidate the downstream pathway involved in necroptosis with contradictory results.
However, most studies have suggested that the mitochondria, in one form or another, play a
pivotal role in necroptosis [102, 105, 106].

23

Figure 5 – Necroptosis Mediators and Signaling Pathway
The best-characterized pathway of necroptosis involves the ligation of TNFα with TNF-R1,
which recruits TRADD, TRAF2/5, cIAP1/2, LUBAC and RIPK1 to form Complex I. cIAP1/2
and LUBAC then polyubiquitinate RIPK1 which results in signaling through the pro-survival
NF-κB pathway. Persistent/severe injury results in RIPK1 deubiquitination by the enzymes
A20 and CYLD. Deubiquitinated RIPK1 interacts with FADD, procaspase-8 and c-FLIPL to
form Complex IIa. c-FLIPL differentially regulates the activation/inhibition of caspase-8
depending on its expression levels. Activated caspase-8 induces apoptosis via activation of
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caspases-3, -6 and -7; however, if caspase-8 activity is disrupted, RIPK1 interacts with RIPK3
to form Complex IIb. RIPK1 and RIPK3 then auto- and trans-phosphorylate each other and
also phosphorylate MLKL, which initiates the downstream signaling in necroptosis [102, 105,
106, 109, 110].
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1.7 – Mitochondria in Cell Death
Mitochondria are highly dynamic organelles that have vital roles in cellular
bioenergetics, metabolism, biosynthesis, and regulation of diverse signals that determine the
fate of the cell. Cellular injury leads to mitochondrial dysfunction that disrupts the
mitochondrial functions integral to the survival of the cell and activates signals that promote
cell death. Although mitochondria are involved in several forms of PCD, their role in apoptosis
and necroptosis is most relevant to IRI (Figures 5 and 7) [104, 106, 111, 112, 113].
1.7.1 – Role of Mitochondria in Apoptosis – Apoptosis can be initiated through two different
pathways - extrinsic (via death receptor stimulation) and intrinsic. Although mitochondria are
involved in both pathways, they have a more critical role in the intrinsic pathway of apoptosis
(Figure 5) [111, 112, 113]. Pathological changes associated with cell injury such as ROSmediated oxidative damage, intracellular calcium overload, and DNA damage (all of which
may result from IRI) can initiate the intrinsic pathway of apoptosis by permeabilization of the
outer mitochondrial membrane (OMM). Mitochondrial outer membrane permeabilization
(MOMP) is normally tightly regulated by the B cell lymphoma 2 (Bcl-2) family of pro- and
anti-apoptotic members. Following an apoptotic stimulus, the pro-apoptotic Bcl-2 associated
X protein (BAX) and Bcl-2 homologous antagonist killer (BAK) undergo conformational
changes and form homo-oligomers that form pores in the OMM. Permeabilization of the OMM
releases pro-apoptotic proteins such as Cytochrome C (Cyt C) and second mitochondriaderived activator of caspases (SMAC)/direct IAP binding protein with low pI (DIABLO) [111,
112, 113, 114]. Cyt C is an essential ETC component that interacts with apoptotic protease
activating factor 1 (Apaf-1), procaspase-9 and dATP to form the apoptosome. The apoptosome
activates procaspase-9 to the 'initiator' caspase-9 that cleaves procaspases-3, -6 and -7 to their
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active forms. SMAC/DIABLO promotes apoptosis by neutralizing the inhibitory effect of IAPs
on caspases [102, 111, 112, 113, 114].
The extrinsic pathway of apoptosis, triggered by death receptor stimulation, is linked
to the intrinsic pathway of apoptosis by the pro-apoptotic Bcl-2 protein, BH3 interactingdomain death agonist (BID). Caspase-8 cleaves BID into its truncated form, tBID, which
promotes the OMM permeabilization by BAX and BAK and release of Cyt C and
SMAC/DIABLO [111, 112, 113, 114].
1.7.2 – Role of Mitochondria in Necroptosis – As explained earlier, most studies suggest a
role for mitochondria in necroptosis. However, even for the studies indicating a mitochondrial
role, the precise signaling pathway is a point of contention (Figures 5 and 7) [106]. The earliest
studies done to investigate the mitochondrial role in necroptosis suggested that the involvement
of ROS generation is secondary to mitochondrial damage and ETC disruption [115, 116, 117,
118, 119]. These studies have shown the formation of necrosome and its translocation to the
mitochondria along with pMLKL following TNFα signaling [106, 115, 116, 117, 120, 121,
122, 123]. Furthermore, the use of the antioxidant butylated hydroxyanisole prevented ROS
generation and TNFα-induced necroptosis [115, 116]. In other studies, the ROS generated were
determined to be mitochondrially derived. Inhibiting cytoplasmic ROS generation by the
enzyme NADPH oxidase did not inhibit TNFα-induced necroptosis; however, suppression of
the ETC complex I and the use of the mitochondria-specific ROS scavenging enzyme,
mitochondrial superoxide dismutase (MnSOD), did [115, 116, 122]. There is also evidence
suggesting the involvement of the mitochondrial enzyme glutamate dehydrogenase 1
(GLUD1) in TNFα-induced ROS production and necroptosis [121].
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The involvement of the mitochondrial factors serine/threonine-protein phosphatase 5
(PGAM5) and Dynamin-related protein 1 (Drp1) in necroptosis have also been studied [123,
124]. According to these studies, following necroptosis induction, the necrosome and pMLKL
translocate to the mitochondria, where they activate PGAM5. PGAM5 then recruits and
activates Drp1 by dephosphorylation of serine 637 of Drp1. Activated Drp1 induces
mitochondrial fragmentation, resulting in necroptosis. In support of these findings, Drp1
inhibition (with Mdivi-1) and deficiency have been shown to reduce TNFα-induced
necroptosis. Furthermore, coimmunoprecipitation assays have indicated a direct interaction
between necrosome and PGAM5 following TNFα signaling [123, 124].
Among the proposed mitochondrial mediators of necroptosis, evidence for the role of
mPTP is the strongest [104, 106]. As explained earlier, IRI induces the formation of mPTP,
which leads to cellular demise via ΔΨm dissipation, ATP depletion, ROS production, and
mitochondrial swelling and rupture, releasing various cell death mediators [20]. Genetic
experiments involving cells and mice deficient for cyclophilin D (CypD), a critical regulator
of mPTP opening, have shown resistance to cell death induced by necroptotic mediators.
Furthermore, these experiments have also shown that the protection conferred by CypD
inhibition or ablation is not additive to that conferred by blocking the upstream signaling
pathway in necroptosis [125, 126, 127].
It is important to note that some studies have indicated that necroptosis can occur
independently of mitochondria. In a study investigating the role of mitochondria in necroptosis,
widespread mitochondrial depletion via mitophagy did not prevent TNFα-induced necroptosis
[128]. The role of mitochondrial ROS, PGAM-Drp1 axis and mPTP formation in necroptosis
is also disputed and not fully established. Several studies have shown that treatment with a
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variety of antioxidants did not attenuate cell death following ROS production in response to
TNFα signaling. Similarly, necroptosis was observed in cells despite PGAM5 and Drp1
knockdown [128, 129, 130, 131]. Although evidence for the role of mPTP in necroptosis is
strongest, findings from one study have questioned its role. This study reveals that
simultaneous RIPK3 and CypD ablation provides greater protection against necroptosis than
separate RIPK3 and CypD depletions in the context of renal IRI [132]. The most compelling
studies disputing the role of mitochondria in necroptosis indicate that necrosome formation is
followed by phosphorylation and oligomerization of MLKL. Oligomerized pMLKL
complexes then translocate to the plasma membrane, where they compromise its integrity by
forming holes [133, 134, 135, 136].

1.8 – Mitochondrial Permeability Transition Pore
The outer and inner membranes of the mitochondria are different from each other in
several aspects. OMM is relatively permeable due to the presence of the voltage-dependent
anion channels (VDAC), which form general diffusion pores for ions and hydrophilic
molecules between the mitochondria and cytosol. The inner mitochondrial membrane (IMM),
on the other hand, is highly impermeable and effectively separates the mitochondrial matrix
from the cytosol. Movement of ions and metabolites across IMM involves specialized
membrane transporters [20, 137, 138]. The ETC complexes are embedded within IMM and are
responsible for establishing the ΔΨm by creating a proton gradient across IMM. This proton
gradient is used by the 'F1/F0 ATP synthase' to generate ATP. Increased permeability of IMM
disrupts the proton gradient and the ΔΨm, resulting in decreased ATP synthesis. It also enables
the loss of ETC components, which results in the incomplete reduction of oxygen and ROS
production [140, 141]. The loss of mitochondrial antioxidants compromises the ROS
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neutralizing ability of the mitochondria and further augments oxidative damage. The 'pore'
responsible for the increased permeability of the IMM is the entity termed 'mPTP' (Figure 6)
[20, 137, 138, 139, 140, 141]. mPTP formation also results in the influx of metabolites (<1.5
kDa) and water into the mitochondrial matrix leading to osmotic swelling. Swelling of the
mitochondrial matrix may not compromise the integrity of IMM because of cristae unfolding,
but it exerts pressure on OMM and ruptures it. This releases cell death mediators, such as the
pro-apoptotic ETC component Cyt C, resulting in cellular demise [20, 137, 138, 139].
1.8.1 – Structural Components of mPTP – While the pathological consequences of mPTP
formation are well established, its exact structural components are still disputed. According to
the classical model, mPTP spans the mitochondrial intermembrane space and comprises of
VDAC in OMM and adenine nucleotide translocator (ANT) in IMM, besides the regulatory
component, CypD, in the mitochondrial matrix. Although genetic tests do not fully support the
roles of VDAC and ANT, the role of CypD in regulating mPTP formation is well established.
[106, 137, 138]. CypD regulation of mPTP formation occurs even in the absence of VDAC
and ANT [20, 106, 137, 138].
Recent studies have suggested that the OMM component of mPTP may be formed by
the pro-apoptotic Bcl-2 proteins BAX and BAK that form MOMP in their active oligomerized
state [138, 142, 143]. According to this more current model, the IMM component is formed by
the c-subunit of F1/F0 ATP synthase. CypD binds with the oligomycin sensitivity-conferring
protein (OSCP) of F1/F0 ATP synthase and triggers mPTP formation through its dimerization.
This model also suggests that the two structural components of mPTP do not form in apposition
to form a contiguous pore [142, 143]. The regulation of mPTP occurs at F1/F0 ATP synthase
in IMM while MOMP is relatively non-selective. Some studies have also suggested that BAX
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and BAK generate a low level of OMM permeability even in their non-oligomerized (inactive)
states, although evidence for this is inconclusive (Figure 6) [137, 138, 139, 142, 143].
1.8.2 – Formation of mPTP in IRI – Under physiological conditions, brief and abrupt mPTP
formation (mPTP flickering) is considered a mitochondrial calcium efflux mechanism and
maintains calcium homeostasis [137, 144]. IRI results in ROS generation and increased
intracellular calcium, the two most potent triggers of prolonged and pathological mPTP
formation [13, 106, 139, 140, 141]. As explained earlier, ischemia results in insufficient ATP
levels, increased intracellular sodium and calcium and decreased intracellular pH. Although
ischemia is associated with increased intracellular calcium, mPTP formation is not observed.
This may be due to the hydrogen ions competing with the calcium ions at the trigger site.
Reperfusion is associated with the additional generation of ROS, further calcium overload and
restoration of the intracellular pH. The removal of the accumulated hydrogen ions enables the
increased intracellular calcium to trigger the formation of mPTP. ROS-mediated oxidative
damage promotes mPTP formation by sensitizing mPTP to increased calcium levels and by
increasing CypD interaction with the IMM component of mPTP (Figure 5) [13, 18, 20].
1.8.3 – Role of mPTP in Necroptosis – As explained earlier, evidence supporting the role of
mitochondria in necroptosis is most indicative of mPTP formation (Figure 5). Recent studies
have suggested that the precise mechanism of necroptosis may involve the release of pronecroptotic mediators following mPTP formation [104, 145, 146]. The putative mitochondrial
pro-necroptotic mediators currently being investigated are apoptosis-inducing factor (AIF) and
endonuclease G (Endo G). AIF and Endo G are mitochondrial proteins that translocate to the
nucleus following their release into the cytosol and mediate DNA fragmentation, a
characteristic finding observed in necroptosis [145, 146]. According to a recent study, CypD
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inhibition prevents AIF and Endo G translocation to the nucleus [145]. Furthermore, as with
RIPK1 and RIPK3 inhibition, CypD and AIF/Endo G silencing are protective against IRI,
suggesting their role in necroptosis [147, 148]. mPTP formation in IRI may also lead to ROS
generation, another potential mediator of necroptosis and ATP depletion that ultimately leads
to unregulated necrosis (Figure 7) [13, 18, 20, 106].
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Figure 6 – Mitochondrial Permeability Transition Pore Components and Structure
The classical model of mPTP involves VDAC in the OMM, ANT in the IMM and the
regulatory component CypD in the mitochondrial matrix. Although genetic tests do not fully
support the roles of VDAC and ANT, CypD regulation of mPTP formation occurs even in the
absence of VDAC and ANT. According to the current model of mPTP, the OMM component
of mPTP may be formed by the pro-apoptotic Bcl-2 proteins BAX and BAK that form MOMP
in their active oligomerized state while the IMM component is formed by F1/F0 ATP synthase.
CypD binds with OSCP of F1/F0 ATP synthase and triggers mPTP formation through its
dimerization. This model also suggests that the two structural components of mPTP do not
form in apposition to form a contiguous pore. The regulation of mPTP occurs at F1/F0 ATP
synthase in IMM, while MOMP is relatively non-selective [137, 138, 142, 143].
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Figure 7 – Role of Mitochondria in Programmed Cell Death Pathways
Mitochondria play a critical role in unregulated necrosis and PCD. MOMP formation
contributes to apoptosis via the release of Cyt C, cIAP1/2 and SMAC/DIABLO. Following
cellular injury (especially IRI), mPTP formation may contribute to ROS production, which
have a role in inducing necroptosis in several cell types. mPTP formation also facilitates the
release of AIF/Endo G, which then translocate to the nucleus and mediate DNA fragmentation,
a characteristic finding observed in necroptosis and parthanatos. Finally, persistent mPTP
formation results in loss of PMF and ΔΨm, resulting in failure of critical energy-dependent
cellular systems and cell death via unregulated necrosis [13, 18, 20, 104, 106, 111, 145, 146,
147, 148, 149].
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1.9 – Apoptosis-Inducing Factor
AIF is a mitochondrial flavoprotein that, under physiological conditions, has essential
pro-survival functions. AIF has oxidoreductase activity and is crucial for the biogenesis and
stabilization of key ETC components, Complex I and Complex III [147, 148]. Harlequin (Hq)
mice, which have a hypomorphic AIF mutation (80% reduction) due to proviral insertion at
the X-linked Aifm1 (AIF gene) locus, display phenotypic changes characteristic of
mitochondrial diseases and disruption in energy metabolism. These mice develop severe
neuromuscular mitochondriopathies and exhibit progressive hair loss, neurodegeneration,
ataxia and blindness due to retinal degeneration [147, 148, 149]. Cardiac and skeletal musclespecific AIF knockout results in cardiomyopathy and skeletal atrophy [146, 147, 148, 151].
Consistent with these findings, in vitro experiments indicate that cells lacking AIF have high
lactic acid production due to ETC disruption and anaerobic glycolysis [145, 146, 147, 148,
149].
Although mitochondrion-localized AIF has pro-survival functions, extra-mitochondrial
AIF is involved in PCD (Figure 8). Following its release into the cytoplasm, AIF translocates
to the nucleus and triggers caspase-independent cell death by inducing DNA damage. AIFmediated DNA degradation has been shown to occur in response to several types of pathologic
insults, including IRI. Mitochondria purified following IRI show a decrease in their AIF
content and presence of AIF in the nucleus [147, 148]. There is limited evidence suggesting
that inhibition of the upstream necroptotic pathway and blocking mPTP formation restricts
AIF-mediated DNA fragmentation [145, 148]. Furthermore, mitochondrial calcium overload,
a potent trigger for mPTP formation, also induces AIF release [145, 147, 148].

35

Figure 8 – Role of Apoptosis-Inducing Factor in Programmed Cell Death
Mitochondrion-localized AIF has essential pro-survival functions in cellular bioenergetics;
however, extra-mitochondrial AIF is involved in PCD. Following its release into the cytoplasm
by a death-inducing signaling event, AIF is cleaved to its truncated form and translocates to
the nucleus where it mediates large-scale DNA fragmentation via activation of an unidentified
endonuclease. Recent studies have suggested that mPTP formation may facilitate the release
of AIF from the mitochondria. AIF translocation to the nucleus is inhibited by HSP-70 and
facilitated by CypA [145, 146, 147, 148].
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1.10 – Study Rationale
A growing body of evidence indicates that necroptosis is a highly inflammatory form
of PCD that contributes to IRI-mediated allograft injury and promotes recipient alloimmune
responses [102, 105]. As such, it represents a relevant therapeutic target in the clinical
management involving organ transplantation. Previous studies from our lab suggest that
necroptosis contributes to kidney IRI and promotes cardiac and renal allograft rejection [103,
104]. We have also shown that inhibition of RIPK3 and CypD prevents necroptosis in murine
microvascular endothelial cells, thereby establishing the significance of these mediators in the
necroptotic pathway. In our previous studies, inhibition of RIPK3 and CypD attenuated
allograft rejection and promoted graft survival [103, 104]. Although the upstream signaling
molecules and pathways involved in necroptosis are well-established, the role of mitochondria
and the downstream mediators involved are mostly unknown [102, 106]. The main objective
of this study was to investigate the precise role of CypD-mediated mPTP formation in
promoting mitochondrial damage and release of mediators involved in DNA fragmentation
associated with hypoxia/reoxygenation-induced necroptosis. We also translated findings from
our previous studies supporting the role of CypD inhibition in promoting graft survival to a
clinically relevant model involving prolonged cold ischemic organ storage followed by
heterotopic transplantation.

1.11 – Hypothesis
We hypothesize that ischemia-reperfusion injury induces mitochondrial damage,
release of mitochondrial factors, and activation of the downstream mechanisms of nuclear
fragmentation, thus promoting allograft injury and transplant rejection.
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1.12 – Study Aims
1. To determine the role of CypD in endothelial cell death following in vitro cold
hypoxia-reoxygenation injury.
2. To determine the effectiveness

of CypD

inhibition in

attenuating IRI-

aggravated transplant rejection and prolonging graft survival.
3. To investigate the mitochondrial mechanism(s) involved in mediating DNA
fragmentation in hypoxia/reoxygenation-induced endothelial cell necroptosis.
4. To determine the effectiveness of inhibiting the mitochondrial mechanism(s) involved
in mediating DNA fragmentation in attenuating IRI-mediated transplant rejection and
prolonging graft survival.

38

Chapter 2
MATERIALS AND METHODS
2.1 – Mice
Wild-type (WT) C57BL/6 (B6), BALB/c and B6 CypD-/- mice were purchased from
the Jackson Laboratory (Bar Harbor, ME, USA). The mice were maintained in the Animal
Care and Veterinary Services facility at Western University. All animal use protocols and
experimental procedures were approved by the institutional Animal Care Committee.

2.2 – Cardiac Transplantation and Post-Operative Monitoring
Donor hearts from WT and CypD-/- mice were heterotopically transplanted into the
abdominal region of BALB/c mice. The mice were anesthetized with a mixture of
ketamine/xylazine before the transplantation procedures. Donor hearts were removed after
clamping the aortae, vena cavae and pulmonary arteries and veins. They were then flushed
with cold normal saline and stored in Lactated Ringer’s buffer (Baxter International Inc.,
Deerfield, IL, USA) at 4°C for 4 hours before heterotopic transplantation into the abdominal
cavity in recipient mice. Aortae from the donor hearts were sutured to the recipient mice
abdominal aortae and the donor heart pulmonary arteries were sutured to the recipient mice
inferior vena cavae. The vena cavae and pulmonary veins in the donor hearts were sutured
shut. The hearts were observed for spontaneous contractions following transplantation before
the recipient mice were sutured close. Cardiac transplantation experiments were performed by
experienced microsurgeons at the Matthew Mailing Centre for Translational Transplantation
Studies at the London Health Sciences Centre according to institutionally approved protocols.
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Following the transplantation procedure, the immunosuppressive sirolimus (rapamycin; LCL
Laboratories, Woburn, MA, USA) at 1 mg/kg was given from the operative day to
postoperative day 9. Graft survival was monitored daily by abdominal palpation for pulse
detection. Cessation of or significant drop in pulsation was considered as graft rejection and
confirmed by histopathological analysis.

2.3 – Histology and Immunohistochemistry
Cardiac allografts in the recipient mice were collected on the day of rejection or at 21
days post-transplantation for pathological analysis. The recipient mice were anesthetized with
a mixture of ketamine/xylazine before the abdominal cavities were opened and the allografts
removed. The isolated cardiac allografts were then flushed with normal saline, fixed with 10%
neutral buffered formalin and embedded in paraffin for sectioning. The tissue sections were
then stained with Hematoxylin & Eosin (H&E) and Verhoeff–Van Gieson elastic stain to
evaluate damage to microvasculature, neointima formation and fibrosis. The tissue sections
were also stained with anti-CD3 and anti-CD68 antibodies (eBioscience, San Diego, CA, USA)
to evaluate and quantify T cell and macrophage infiltration, respectively. Tissue sectioning and
staining was done by a laboratory technician according to the manufacturers’ protocols. Graft
injury was evaluated based on the change in endothelium and leukocyte infiltration compared
to naïve tissue by a pathologist in a blinded manner. The following changes were evaluated
and quantified: damage to microvasculature, neointima formation, fibrosis, and leukocyte
infiltration. The criteria used scored the injury on a scale of 0-4 as follows – 0: no change, 1:
0-24% change, 2: 25-49% change, 3: 50-74% change, and 4: >75% change.

2.4 – Endothelial Cell Culture
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Endothelial cells were isolated as per the established protocol described previously
[103]. Endothelial cells were isolated from the ventricles of 3-4 weeks old WT and CypD-/mice. The major vessels (aortae, pulmonary veins and vena cavae) and atrial tissue were cut
out and discarded. The ventricles were washed thoroughly with Dulbecco’s Phosphate
Buffered Saline (PBS; Thermo Fisher Scientific, Mississauga, ON, Canada) and minced before
incubation in D‐Hank's digestion buffer containing Collagenase II (1 mg/mL) and Dispase II
(2 mg/mL) (Thermo Fisher Scientific, Mississauga, ON, Canada) at 37°C for 40 mins. The cell
suspension was filtered using a 100 µm nylon mesh filter and then incubated with anti‐CD31
coated Dynal magnet beads (Invitrogen, Burlington, ON, Canada) for 30 mins. The isolated
CD31-positive cells were then washed and grown in Endothelial Cell Growth Basal Medium2 (EBM-2; Lonza, Mississauga, ON, Canada) containing 5% fetal bovine serum (FBS), 0.04%
hydrocortisone, 0.4% human fibroblast growth factor (hFGF), 0.1% vascular endothelial cell
growth factor (VEGF), 0.1% R3‐insulin-like growth factor-1 (R3-IFG‐1), 0.1% ascorbic acid,
0.1% human epidermal growth factor (hEGF) and 0.1% gentamicin-sulfate amphotericin 1000
(GA‐1000). The phenotype of isolated endothelial cells was confirmed by flow cytometry
analysis of CD31, CD102 and CD105 (eBioscience, San Diego, CA, USA). The positively
staining cells were then immortalized by origin-defective SV40-plasmid transfection.
Normal cell culture medium used to grow endothelial cells was prepared by
supplementing 1 g/L glucose Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher
Scientific, Mississauga, ON, Canada) with 10% FBS and 1% penicillin/streptomycin. Cells
were passaged a maximum of ten times with 0.25% trypsin (Life Technologies, Burlington,
ON, Canada) before being discarded.
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CypD-/- endothelial cells did not display any phenotypic changes as compared to WT
endothelial cells. The growth and baseline turnover of the CypD-/- endothelial cells were
comparable to the WT endothelial cells.

2.5 – RNA Interference Silencing
WT endothelial cells were seeded on 6-well plates and grown to 60-80% confluency in
normal cell culture medium. The cells were washed with PBS before transfection with ONTARGETplus Mouse Aifm1 siRNA (Dharmacon, Lafayette, CO, USA) using EndoFectin™
Max transfection reagent (Genecopoeia, Rockville, MD, USA) in Opti-MEM® media
(Invitrogen, Carlsbad, CA, USA). ON-TARGETplus Mouse Aifm1 siRNA was used at various
concentrations from 100 nM – 800 nM. siRNA-induced silencing of Aifm1 expression was
confirmed by quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and
Western Blot, respectively at 24-, 48-, 72- and 96-hours post-transfection. Based on RT-qPCR
and Western Blot results, the manufacturer-recommended dose of 200 nM was used for this
study. The AIF-silenced cells were harvested at 48-hours post-transfection by 0.25% trypsin
for cell death assays.

2.6 – RT-qPCR
siRNA-induced silencing of Aifm1 expression was confirmed by RT-qPCR at 24-, 48, 72- and 96-hours post-transfection. Total RNA from scrambled siRNA-transfected cells and
Aifm1 siRNA-transfected cells was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA). The concentration and purity of the isolated RNA was measured using the NanoDrop™
2000 Spectrophotometer (Thermo Fisher Scientific, Mississauga, ON, Canada). cDNA was
generated from RNA using SuperScript™ II Reverse Transcriptase (Thermo Fisher Scientific,
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Mississauga, ON, Canada). RT-qPCR was performed using Brilliant II SYBR® Green QPCR
Master Mix (ABM, Vancouver, BC, Canada) and CFX Connect™ Real-Time PCR Detection
System (Bio-Rad, Hercules, CA, USA). The Aifm1 primers used are as follows: Aifm1 forward
primer (5’ – 3’) GTA GAT CAG GTT GGC CAG AAA CTC and Aifm1 reverse primer (5’ –
3’) GGA TTA AAG GCA TGT GCC AAC ACG. β-actin was used as endogenous control for
gene expression analysis. β-actin primers used are as follows: β-actin forward primer (5’ – 3’)
CCA GCC TTC CTT CCT GGG TA and β-actin reverse primer (5’ – 3’) CTA GAA CAT
TTG CGG TGC A. The ΔCt values for Aifm1 and β-actin were used to calculate the 2-ΔΔCt to
get the expression fold change.

2.7 – Western Blots
siRNA-induced silencing of AIF protein expression was confirmed by Western Blot
analysis at 24-, 48-, 72- and 96-hours post-transfection. Total protein from scrambled siRNAtransfected cells and Aifm1 siRNA-transfected cells was extracted using RIPA Lysis and
Extraction Buffer (Thermo Fisher Scientific, Mississauga, ON, Canada) with Thermo
Scientific™ Pierce Protease Inhibitor Cocktail Tablets (Thermo Fisher Scientific, Mississauga,
ON, Canada). The concentration and purity of the isolated protein was measured by Bradford
Dye Protein Assay using GENESYS™ 10S UV-Vis Spectrophotometer (Thermo Fisher
Scientific, Mississauga, ON, Canada). The isolated protein samples were denatured by boiling
in a loading buffer (4% SDS, 5% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue,
0.125 M Tris-HCl; pH adjusted to 6.8) at 95°C for 5 minutes. The protein samples were then
equally loaded (30-40 μg) in the wells of 10% SDS-PAGE gel and the gel was run at 100 V
for ~1.5 hours in the electrophoresis apparatus with 1X running buffer (25 mM Tris base, 192
mM glycine, 0.1% SDS; pH adjusted to 8.3). The separated protein samples were transferred
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onto polyvinylidene fluoride (PVDF; activated with methanol) membrane in a transfer
apparatus filled with ice-cold 1X transfer buffer (25 mM Tris base, 192 mM glycine, 20%
methanol; pH adjusted to 8.3). The transfer cassette was prepared with the PVDF membrane,
filter paper and fiber pads and the transfer apparatus was placed in ice and run at 70 V for ~1.5
hours. Once the protein samples were transferred onto the PVDF membrane, the membrane
was blocked with 5% bovine serum albumin (BSA) in TBS-T (20 mM Tris base, 150 mM
NaCl, 0.1% Tween-20) on a standard analogue shaker (VWR, Mississauga, ON, Canada) at
room temperature for 1 hour. After blocking, the PVDF membrane was incubated with primary
rabbit anti-mouse AIF antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:1000
dilution in 2.5% BSA in TBS-T overnight at 4°C. The PVDF membrane was then washed with
TBS-T 3X for 15 minutes each time before incubation with HRP-conjugated secondary goat
anti-rabbit antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:1000 dilution in
2.5% BSA in TBS-T at 4°C for 1 hour. The PVDF membrane was then washed with TBS-T
3X for 10 minutes each time before it was developed for protein visualization using the HRP
chemiluminescent substrate (EMD Millipore, Burlington, MA, USA) and imaged in the
FluorChem M Imaging System. The housekeeping proteins, β-actin and/or GAPDH, were used
as loading controls. Murine anti-mouse β-actin antibody (MilliporeSigma, Etobicoke, ON,
Canada) was used to detect β-actin and rabbit anti-mouse GAPDH antibody (Abcam,
Cambridge, UK) was used to detect GAPDH.
To detect the expression of pMLKL in endothelial cells undergoing necroptosis,
endothelial cell cultures (in 6-well plates) were subjected to the in vitro cold hypoxiareoxygenation injury model described earlier. The reoxygenation phase was limited to 12-18
hours at which point, the total protein was isolated and analyzed as described earlier. The
primary antibody used to detect pMLKL was rabbit anti-mouse pMLKL (S345) antibody
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(Abcam, Cambridge, UK). The primary antibody used to detect MLKL was rat anti-mouse
MLKL antibody (MilliporeSigma, Etobicoke, ON, Canada).

2.8 – In Vitro Cold Hypoxia-Reoxygenation Injury Model
To model ischemia injury, endothelial cell cultures were incubated in oxygen-depleted,
glucose-free DMEM under hypoxic condition in Whitley H45 Hypoxystation (Don Whitley
Scientific, United Kingdom) or anaerobic GENbags (BioMérieux, France). For cold hypoxia,
the Hypoxystation was set at 10°C for 24 hours and the GENbags were placed in a refrigerator
set at 4°C. To model reperfusion injury, the endothelial cell cultures were removed from the
hypoxic environment and the oxygen-depleted, glucose free DMEM was replaced with normal
cell culture medium in a normoxic incubator. Human TNFα (hTNFα; PeproTech, Rocky Hill,
NJ, USA) at 50-100 μg/mL and recombinant mouse IFNγ (PeproTech, Rocky Holl, NJ, USA)
at 50-100 μg/mL were added during both the hypoxia and the reoxygenation phases to simulate
the IRI microenvironment in vitro. Pan-caspase inhibition was achieved by adding the pancaspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone (z-VADfmk; BD Biosciences, Mississauga, ON, Canada) at 30 μM. RIPK1 inhibition was achieved by
adding the RIPK1 specific kinase inhibitor necrostatin-1s (Nec-1s; Merck Millipore,
Etobicoke, ON, Canada) at 10 μM. CypD mediated mPTP formation was inhibited by
Cyclosporin A (CsA; Sigma-Aldrich, Oakville, ON, Canada) at 0.5-20 μM. The
immunosuppressive FK-506 (Sigma-Aldrich, Oakville, ON, Canada), which is a calcineurin
inhibitor but not a CypD inhibitor was used as CsA control. The ROS scavengers used include
the

superoxide

dismutase

mimetic

1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine

(TEMPOL; Sigma-Aldrich, Oakville, ON, Canada) at 5-20 μM, the glutathione precursor Nacetyl-L-cysteine (NAC; Sigma-Aldrich, Oakville, ON, Canada) and the mitochondrion45

specific superoxide dismutase mimetic mito-TEMPOL (Sigma-Aldrich, Oakville, ON,
Canada) at 5-20 μM. To inhibit Drp1-mediated mitochondrial division, the Mitochondrial
Division Inhibitor 1 (Mdivi-1; Sigma-Aldrich, Oakville, ON, Canada) was used at 10-40 μM.
The CypA inhibitor, Alisporivir (DebioPharm, Lausanne, Switzerland) was used at 0.25-4 μM
to prevent AIF translocation. Based on available literature and dose-response curves indicating
maximum reduction in hypoxia/reoxygenation-induced cell death, a dose of 1 μM for
Alisporivir was chosen for the study. The PARP-1 inhibitor, 3-aminobanzamide (3-ABA;
MilliporeSigma, Etobicoke, ON, Canada) at 10-100 μM was used to inhibit parthanatos. The
inhibitors were added during both the hypoxia and the reoxygenation phases. Endothelial cells
from CypD-/- mice and AIF-silenced endothelial cells were also subjected to the in vitro cold
hypoxia-reoxygenation injury model.

2.9 – Cell Death Assay
Cell death was detected and quantified by real-time imaging in the IncuCyte ZOOM®
Live Cell Analysis System (Essen Bioscience, Ann Arbor, MI, USA). SYTOX™ Green
Nucleic Acid Stain (Thermo Fisher Scientific, Mississauga, ON, Canada) at 100 nM was used
to indicate dead cells. SYTOX™ Green is impermeable to live cells but crosses the
compromised plasma membranes of dead cells and stains the nucleic acid. It is excited with
488 nm laser light in the IncuCyte and fluoresces green which helps in distinguishing dead
cells from live cells. Cell death was also detected with propidium iodide (PI) or annexin V
labeling (BD Bioscience, Mississauga, ON, Canada) and analyzed by flow cytometry
(Beckman Coulter, Mississauga, ON, Canada).

2.10 – Immunocytochemistry
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To show AIF translocation to the nucleus from the mitochondria in endothelial cells
undergoing necroptosis, endothelial cell cultures (in 96-well plates) were subjected to the in
vitro cold hypoxia-reoxygenation injury model described earlier. The reoxygenation phase was
limited to 24 hours at which point, the cells were fixed with 4% paraformaldehyde in PBS (pH
7.4) for 30 minutes at room temperature. The cells were washed 3X for 5 minutes each time
with PBS and then incubated with 0.1-0.25% Triton

X-100 non-ionic surfactant in PBS for

10 minutes at room temperature for permeabilization. The cells were washed again 3X for 5
minutes each time with PBS. To reduce non-specific antigen binding and background
fluorescence, the cells were incubated in a blocking solution (1% BSA, 22.52 mg/mL glycine
and 0.1% Tween 20) for 30-45 minutes at room temperature. Following blocking, the cells
were incubated with primary rabbit anti-mouse AIF antibody diluted in 1% BSA in PBS with
0.1% Tween-20 at 1:1000 concentration ratio for 1 hour at room temperature in a humidified
chamber. The cells were then washed 3X for 5 minutes each time and then incubated with
secondary donkey anti-rabbit PE-conjugated antibody (Abcam, Cambridge, United Kingdom)
diluted in 1% BSA in PBS at 1:60 concentration ratio for 1 hour at room temperature in a dark
humidified chamber. The cells were washed again 3X for 5 minutes each time with PBS. For
nuclear counterstaining, the cells were incubated with 300 nM DAPI staining solution (Thermo
Fisher Scientific, Mississauga, ON, Canada) for 5 minutes at room temperature in a humidified
chamber and then washed 3X for minutes each time with PBS. Nikon Inverted Research
Microscope ECLIPSE Ts2R (Nikon, Tokyo, Japan) was used to capture fluorescent images at
20-40X magnification.

2.11 – DNA Gel Analysis
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To analyze AIF-mediated DNA degradation into ~50 kbp fragments, endothelial cell
cultures (in 6-well plates) were subjected to the in vitro cold hypoxia-reoxygenation injury
model described earlier. The reoxygenation phase was limited to 12-18 hours at which point,
DNA was isolated using the Qiagen Blood & Cell Culture DNA Mini Kit (Qiagen, Hilden,
Germany). The concentration and purity of the isolated DNA was measured using the
NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Mississauga, ON, Canada).
The size of the isolated DNA fragments was characterized by electrophoretic separation using
0.3% agarose gel run at 3-4 V/cm. For DNA visualization, the agarose gel was stained with
SYBR™ Safe DNA Gel Stain and imaged in the FluorChem M Imaging System.

2.12 – Statistical Analysis
The experimental values are expressed as mean ± SD. Data was analyzed using the
Student’s t-test for unpaired values, and 1- and 2-way ANOVA with Tukey’s post-hoc
corrections test. The Mantel-Cox Log Rank test was used to determine graft survival
differences. Differences were considered significant when p-value ≤ 0.05.
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Chapter 3
RESULTS
3.1 – In Vitro Cold Hypoxia-Reoxygenation Injury Promotes Necroptosis in
Endothelial Cells
Endothelial cells from WT B6 mice were isolated and subjected to the in vitro cold
hypoxia-reoxygenation injury model described earlier. TNFα, IFNγ, z-VAD-fmk and Nec-1s
were added during the hypoxia as well as the reperfusion phases. Murine TNFα (mTNFα) can
bind to both TNF-R1 and TNF-R2 [225, 226, 227]. While TNF-R1 signaling induces cell death,
TNF-R2 signaling promotes cell survival [223, 224]. To ensure signaling through the TNF-R1,
human TNFα (hTNFα) was used, which specifically binds to murine TNF-R1 (with limited
TNF-R2 binding) [225, 226, 227]. SYTOX™ Green staining was used to indicate and measure
cell death in the IncuCyte. Treatment of endothelial cells with the proinflammatory cytokines
hTNFα and IFNγ increased cell death compared to untreated cells (Figure 9). The addition of
z-VAD-fmk to hTNFα + IFNγ treated cells increased cell death compared to cells treated only
with hTNFα + IFNγ. z-VAD-fmk is a pan-caspase inhibitor and prevents apoptosis; therefore,
the increase in cell death following treatment with z-VAD-fmk was suggestive of necroptosis.
This was confirmed with the addition of the RIPK1 inhibitor Nec-1s. The addition of Nec-1s
significantly reversed the cell death observed in the hTNFα + IFNγ + z-VAD-fmk treated cells.
Cell death during and immediately following the cold hypoxia phase was minimal and
progressively increased during the reperfusion phase in all treatment groups (Figure 9A). Cell
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death in the first 36 hours was negligible in the absence of cold hypoxia-reoxygenation injury
in all treatment groups

.
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Figure 9 – Cold Hypoxia-Reoxygenation Injury Promotes Necroptosis in Endothelial
Cells
(A) WT B6 endothelial cells were seeded in a 96-well plate in triplicates at 70-80% confluency.
To model in vitro ischemia injury, endothelial cell cultures were incubated in oxygen-depleted,
glucose-free DMEM during hypoxia. The cell culture plates were subjected to cold hypoxia
for 24 hours in anaerobic GENbags placed in a refrigerator set at 4°C. To model in vitro
reperfusion injury, the endothelial cell cultures were removed from the hypoxia environment
and the oxygen-depleted, glucose free culture medium was replaced with normal cell culture
medium before the endothelial cell cultures were transferred to a normoxic incubator set at
37°C, 20% O2 and 5% CO2. hTNFα (T) at 100 μg/mL, IFNγ (I) at 100 μg/mL, z-VAD-fmk (Z)
at 30 μM and Nec-1s (N) at 10 μM were added during both the hypoxia and the reoxygenation
phases to simulate the IRI microenvironment in vitro. SYTOX™ Green Nucleic Acid Stain at
100 nM was used as a nuclear counterstain to indicate dead cells. Cell death (during the
reoxygenation phase; time in hours on X-axis represents reoxygenation time following 24
hours of cold hypoxia at 4°C) was detected and quantified in the IncuCyte ZOOM® Live Cell
Analysis System. For positive control, 1% Triton

X-100 (Tx100) non-ionic surfactant was

used to induce 100% cell death and used to calculate percent cell death in all the treatment
groups. (B) Data at 36 hours post-reperfusion are shown as mean ± SD and representative of
at least 3 independent experiments; n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = nonsignificant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test.
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Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells
The potential mitochondrial mediators of necroptosis include the PGAM5-Drp1 axis
and ROS [106, 115, 116, 117, 118, 119, 123, 124]. ROS are also generated following mPTP
formation [13, 18, 20, 106, 125, 127]. To determine the role of the PGAM5-Drp1 axis in
necroptosis, the Drp1 inhibitor, Mdivi-1, was used. The addition of Mdivi-1 to hTNFα + IFNγ
+ z-VAD-fmk treated cells did not reverse the hypoxia/reoxygenation-induced necroptosis
(Figure 10A). This finding ruled out the role of the PGAM5-Drp1 axis in endothelial cell
necroptosis following cold hypoxia-reoxygenation injury.
The generation of ROS and ROS-mediated injury have been the most crucial focus of
basic and clinical research studies aimed at understanding the molecular mechanisms of
reperfusion injury. The role of ROS-mediated cellular injury in inducing apoptosis in the
setting of IRI has been extensively documented [13, 18, 110, 111, 112, 113, 114]. As explained
earlier, the role of ROS in inducing necroptosis has been studied in several cell types following
various types of injuries but particularly IRI [102, 103, 104, 105, 106, 109, 154, 156, 157, 158,
194, 195, 196]. These studies, however, have yielded conflicting results indicating that the role
of ROS in necroptosis is dependent on cell-type and the cause of injury.
To determine the role of ROS in hypoxia/reoxygenation-induced necroptosis in
endothelial cells, the ROS scavengers, TEMPOL and NAC were used. The addition of
TEMPOL or NAC to hTNFα + IFNγ + z-VAD-fmk treated cells did not reverse necroptosis
following the in vitro cold hypoxia-reoxygenation injury (Figure 10B&C). The addition of the
mitochondrion-specific ROS scavenger, mito-TEMPOL, to hTNFα + IFNγ + z-VAD-fmk
treated cells also did not reverse the hypoxia/reoxygenation-induced necroptosis (Figure 10D).
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This finding ruled out the role of ROS in hypoxia/reoxygenation-induced necroptosis in
endothelial cells. It also established that mitochondrial ROS (following mPTP formation and
ETC dysfunction) did not contribute to hypoxia/reoxygenation-induced necroptosis in
endothelial cells.
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Figure 10 – PGAM5-Drp1 Axis and ROS Do Not Contribute to Hypoxia/ReoxygenationInduced Necroptosis in Endothelial Cells
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation model and
cell death was detected and quantified as described earlier in Figure 9. Data at 36 hours postreperfusion are shown as mean ± SD and representative of at least 3 independent experiments.
(A) Drp1 inhibitor – Mdivi-1 at 10 μM, 20 μM and 40 μM was added during both the hypoxia
and the reoxygenation phases to inhibit PGAM5-Drp1-induced mitochondrial fragmentation.
n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way
ANOVA; Tukey’s multiple comparisons test. (B) ROS scavenger – TEMPOL at 5 μM, 10 μM
and 20 μM was added during both the hypoxia and the reoxygenation phases to inhibit ROSmediated cell damage and death. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = nonsignificant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test. (C) ROS
scavenger – NAC at 5 μM, 10 μM and 20 μM was added during both the hypoxia and the
reoxygenation phases to inhibit ROS-mediated cell damage and death. n = 3; ***p ≤ 0.001,
**p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s
multiple comparisons test. (D) Mitochondrion-specific ROS scavenger – mito-TEMPOL at 5
μM, 10 μM and 20 μM was added during both the hypoxia and the reoxygenation phases to
inhibit mitochondrial ROS-mediated cell damage and death. n = 3; ***p ≤ 0.001, **p ≤ 0.002,
*p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple
comparisons test.
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3.3 – CypD-Mediated mPTP Formation Contributes to Hypoxia/ReoxygenationInduced Necroptosis in Endothelial Cells
As described earlier, studies have firmly established the role of CypD in regulating
mPTP formation [20, 125, 137, 138, 142]. Of the putative mitochondrial mediators involved
in necroptosis, the role of CypD-mediated mPTP formation is the most well-studied. As with
ROS, studies investigating the role of CypD-mediated mPTP in necroptosis have yielded
contradictory results [104, 106, 128, 132, 133, 134, 135, 136]. Persistent/prolonged mPTP
formation leads to the incomplete reduction of oxygen and also provides a link to ROS
generation, which lead to cellular damage, are a strong trigger for necroptosis and are
investigated as the downstream mediators of necroptosis [13, 18, 20, 104, 106, 140, 141].
To study the role of CypD in hypoxia/reoxygenation-induced necroptosis in endothelial
cells, CsA was used. CsA is a potent CypD inhibitor and blocks mPTP formation [13, 18, 20,
104, 137, 138, 211]. As with Nec-1s, the addition of CsA to hTNFα + IFNγ + z-VAD-fmk
treated cells reversed the hypoxia/reoxygenation-induced necroptosis in endothelial cells
(Figure 11A). Besides, blocking mPTP formation, CsA is a calcineurin inhibitor and a potent
immunosuppressive drug [211, 212]. To rule out the participation of calcineurin in necroptosis,
the non-CypD binding calcineurin inhibitor, FK-506, was used [104, 211]. The addition of FK506 to hTNFα + IFNγ + z-VAD-fmk treated cells did not inhibit hypoxia/reoxygenationinduced necroptosis in endothelial cells.
Phosphorylation of MLKL is an established event in necroptosis [102, 104, 105, 106].
In the hTNFα + IFNγ + z-VAD-fmk treated cells, which were undergoing
hypoxia/reoxygenation-induced necroptosis, pMLKL protein expression was noted (Figure
11B&C). The addition of Nec1s to the hTNFα + IFNγ + z-VAD-fmk treated cells, significantly
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reduces the level of hypoxia/reoxygenation-induced necroptosis and the level of pMLKL
protein expression (Figure 11B&C).
To confirm the role of CypD in necroptosis, endothelial cells from CypD-/- mice were
subjected to the in vitro cold hypoxia-reoxygenation injury model. As with CypD inhibition
by CsA, CypD-/- endothelial cells resisted hypoxia/reoxygenation-induced necroptosis (Figure
11D). In our study, the level of necroptosis inhibition by Nec-1s is comparable to the level of
necroptosis inhibition by CypD inhibition and ablation (Figure 11A&D). This finding confirms
that CypD contributes to hypoxia/reoxygenation-induced necroptosis in endothelial cells.

58

A

B

C

D

59

Figure 11 – CypD Deficiency Prevents Hypoxia/Reoxygenation-Induced Necroptosis in
Endothelial Cells
WT and CypD-/- B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation
model and cell death was detected and quantified as described earlier in Figure 9. Data at 36
hours post-reoxygenation are shown as mean ± SD and representative of at least 3 independent
experiments. (A) CypD inhibitor – CsA at 10 μM was added during both the hypoxia and the
reoxygenation phases. For control, the non-CypD binding calcineurin inhibitor FK506 at 10
μM was during both the hypoxia and the reoxygenation phases. n = 3; ***p ≤ 0.001, **p ≤
0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple
comparisons test. CsA dose (10 μM) was optimized (dose-response curves showing maximum
reduction in cell death following cold hypoxia-reoxygenation injury) after using it at various
concentrations from 0.5-20 μM; corresponding doses were used for FK506. (B) WT
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model
described earlier in Figure 9. The reoxygenation phase was limited to 12-15 hours, at which
point the total protein was isolated and Western Blot analysis was performed for detection of
pMLKL protein. GAPDH was used as loading control. (C) The level of pMLKL protein
expression was quantified in the TIZ and TIZN groups. n = 3; **p ≤ 0.05; Student’s t test for
paired values. (D) Endothelial cells were isolated from CypD-/- mice and were subjected to the
same in vitro cold hypoxia-reoxygenation injury model. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p
≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way ANOVA; Tukey’s multiple comparisons
test.

60

3.4 – AIF Contributes to Hypoxia/Reoxygenation-Induced Necroptosis in
Endothelial Cells
Necroptosis exhibits morphological features of unregulated necrosis. Characteristic
findings of necroptotic death include cell membrane rupture and permeabilization, oncosis and
vacuolization of the cytoplasm and organelles, mitochondrial swelling and DNA fragmentation
[102, 105, 109, 110, 157]. Extra-mitochondrial AIF translocates to the nucleus and induces
caspase-independent cell death by inducing large-scale DNA fragmentation (~50 kbp
fragments) [147, 148]. AIF-mediated DNA degradation has been shown to occur in response
to several types of pathologic insults, including IRI [145, 146, 147, 148, 173, 174, 175, 176,
177, 178]. Recent studies have also indicated that mPTP formation facilitates AIF release from
the mitochondria by serving as a morphological conduit [145, 177]. Therefore, we decided to
investigate the role of AIF in hypoxia/reoxygenation-induced necroptosis in endothelial cells
using the in vitro cold hypoxia-reoxygenation injury model.
To date, no effective pharmacological inhibitor of AIF has been recognized [147, 148].
Therefore, to study the role of AIF in hypoxia/reoxygenation-induced necroptosis in
endothelial cells, Aifm1 was silenced in WT B6 endothelial cells using siRNA. AIF silencing
was confirmed by RT-qPCR and Western Blot (Figure 12). AIF-silenced endothelial cells were
subjected to the in vitro cold hypoxia-reoxygenation injury model. Compared to scrambled
siRNA-transfected endothelial cells, AIF-silenced endothelial cells show a significant
reduction in cell death in all treatment groups, indicating inhibition of necroptosis in the AIFsilenced cells. The level of cell death in the AIF-silenced hTNFα + IFNγ + z-VAD-fmk group
is similar to the level of cell death in the WT hTNFα + IFNγ + z-VAD-fmk + Nec-1s group
(Figure 13A). This finding indicates that AIF has a critical role in the necroptotic pathway.
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Recent studies have established that AIF translocation to the nucleus requires CypA
and is inhibited by HSP-70 [147, 148, 152]. Since there are no known AIF inhibitors, CypA
inhibition can be used to indirectly evaluate the role of AIF. Alisporivir is a nonimmunosuppressive cyclophilin binding molecule that binds to CypA, an essential co-factor
for Hepatitis C virus replication [221, 222]. Several in vitro and in vivo studies have explored
the therapeutic potential of Alisporivir in patients with chronic hepatitis C viral infection [148,
221, 222]. To evaluate the role of AIF in hypoxia/reoxygenation-induced necroptosis in
endothelial cells, we used Alisporivir. The addition of Alisporivir to the hTNFα + IFNγ + zVAD-fmk treatment group considerably reduces the level cell death in WT endothelial cells
following the in vitro cold hypoxia-reoxygenation injury (Figure 13B). This finding establishes
that AIF has a critical role in hypoxia/reoxygenation-induced necroptosis in endothelial cells.
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Figure 12 – siRNA-Induced Silencing of Aifm1
WT B6 endothelial cells were transfected with 200 nM ON-TARGETplus Mouse Aifm1 using
EndoFectin™ Max transfection reagent in Opti-MEM® media. Transfected cells were
harvested for in vitro cold hypoxia-reoxygenation injury experiments at 48 hours posttransfection. (A) siRNA-induced silencing of Aifm1 was confirmed by RT-qPCR at 48 hours
post-transfection. β-actin was used as endogenous control for gene expression analysis. Data
at 48 hours post-transfection are shown as mean ± SD and representative of 3 independent RTqPCR experiments. n = 3; **p ≤ 0.05; Student’s t test for paired values. (B) The reduction in
the protein expression of AIF-silenced cells was confirmed by Western Blot analysis at 72
hours post-transfection. β-actin was used as loading control. (C) The reduction in the level of
AIF protein expression at 72 hours following siRNA-induced silencing of Aifm1 was measured
in 3 independent experiments. n = 3; **p ≤ 0.05; Student’s t test for paired values.
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Figure 13 – AIF Silencing Prevents Hypoxia/Reoxygenation-Induced Necroptosis in
Endothelial Cells
WT, scrambled siRNA-transfected cells and AIF-silenced (Aifm1 siRNA-transfected) B6
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model and
cell death was detected and quantified as described earlier in Figure 9. Data at 36 hours postreperfusion are shown as mean ± SD and representative of at least 3 independent experiments.
(A) Scrambled siRNA-transfected and AIF-silenced B6 endothelial cells were harvested 48
hours post-transfection and subjected to the in vitro cold hypoxia-reoxygenation injury model.
n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way
ANOVA; Tukey’s multiple comparisons test. (B) CypA inhibitor – Alisporivir at 1 μM was
added during both the hypoxia and the reoxygenation phases to inhibit CypA-mediated AIF
translocation to the nucleus. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant
(p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test.
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3.5 – AIF Translocation to the Nucleus in Hypoxia/Reoxygenation-Induced
Necroptosis in Endothelial Cells
Following its release into the cytosol from the mitochondria, AIF translocates to the
nucleus and induces DNA degradation [147, 148]. To confirm the role of AIF in necroptosis,
WT endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model
and immunocytochemistry was used to observe AIF translocation to the nucleus in various
treatment groups. In untreated cells, AIF localizes to the mitochondria in the cytoplasm (Figure
14). AIF translocation to the nucleus is observed in the hTNFα + IFNγ and hTNFα + IFNγ +
z-VAD-fmk treatment groups. AIF translocation and overall cell death (necroptosis) is
considerably reduced in the hTNFα + IFNγ + z-VAD-fmk + Nec-1s and hTNFα + IFNγ + zVAD-fmk + Alisporivir treatment groups (Figure 14). Inhibition of AIF translocation to the
nucleus following treatment with Nec-1s indicates that AIF is the downstream mitochondrial
mediator involved in hypoxia/reoxygenation-induced necroptosis in endothelial cells.
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Figure 14 – AIF Translocation to the Nucleus in Hypoxia/Reoxygenation-Induced
Necroptosis in Endothelial Cells
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury
model described earlier in Figure 9. Alisporivir at 1 μM was added during both the hypoxia
and the reoxygenation phases. The reoxygenation phase was limited to 24 hours at which point
the cells were fixed with 4% formaldehyde solution and permeabilized with 0.1-0.25%
Triton

X-100 non-ionic surfactant. To reduce non-specific antigen binding and background

fluorescence, the cells were incubated with a blocking solution comprised of 1% BSA, 22.52
mg/mL glycine and 0.1% Tween 20 in D-PBS. The cells were incubated with primary rabbit
anti-murine AIF antibody diluted in 1% BSA in D-PBS with 0.1% Tween 20 at 1:1000
concentration ratio for 1 hour at room temperature in a humidified chamber. The cells were
then incubated with secondary donkey anti-rabbit PE-conjugated antibody diluted in 1% BSA
in D-PBS at 1:60 concentration ratio for 1 hour at room temperature in a dark humidified
chamber for immunofluorescence. For DAPI counterstaining, the cells were incubated with
300 nM DAPI staining solution for 5 minutes at room temperature in a humidified chamber.
Nikon Inverted Research Microscope ECLIPSE Ts2R was used to capture images at 20-40X
magnification. (A) Representative individual cell images at 80X magnification are shown.
Cells undergoing hypoxia/reoxygenation-induced necroptosis (hTNFα + IFNγ + z-VAD-fmk
treatment group) are shown. (B) Representative microscopic field images at 40X magnification
are shown. All treatment groups are shown.
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3.6 – AIF Induces Large-Scale DNA Degradation in Hypoxia/ReoxygenationInduced Necroptosis in Endothelial Cells
To further confirm the role of AIF in hypoxia/reoxygenation-induced necroptosis, WT
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model and
DNA degradation was characterized by gel electrophoresis. A distinct ~50 kbp band is
observed in the hTNFα + IFNγ + z-VAD-fmk treatment group. The intensity of the 50 kbp
band is considerably decreased in the hTNFα + IFNγ + z-VAD-fmk + Nec-1s and hTNFα +
IFNγ + z-VAD-fmk + Alisporivir groups (Figure 15). This finding indicates that
hypoxia/reoxygenation-induced necroptosis in endothelial cells involves AIF-mediated DNA
degradation into ~50 kbp fragments.
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Figure 15 – AIF Induces Large-Scale DNA Degradation During Hypoxia/ReoxygenationInduced Necroptosis in Endothelial Cells
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury
model described earlier in Figure 9. Alisporivir at 1 μM was added during both the hypoxia
and the reoxygenation phases. The reoxygenation phase was limited to 12-18 hours at which
point, DNA was isolated using the QIAGEN Blood & Cell Culture DNA Mini Kit. The size of
the isolated DNA fragments was characterized by electrophoretic separation using 0.3%
agarose gel run at 3-4 V/cm.
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3.7 – Parthanatos Does Not Contribute to Hypoxia/Reoxygenation-Induced
Endothelial Cell Death
ROS-mediated oxidative damage to DNA in the setting of IRI induces PARP-1
activation [106, 149, 180, 181, 182]. PARP-1 activation causes ADP ribosylation of 'damaged'
chromatin, modulating its structure and facilitating its interaction with DNA repair enzymes.
However, if the DNA damage is severe, the excessive PAR moieties in the nucleus translocate
to the mitochondria and mediate AIF release, ultimately leading to a form of regulated necrosis
termed parthanatos [149]. We investigated the role of parthanatos in endothelial cell death
using our in vitro cold hypoxia-reoxygenation injury model. The addition of the PARP-1
inhibitor, 3-ABA to hTNFα + IFNγ + z-VAD-fmk treated cells, did not reverse the
hypoxia/reoxygenation-induced necroptosis (Figure 16). This indicates that parthanatos does
not contribute to hypoxia/reoxygenation-induced endothelial cell death.
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Figure 16 – Hypoxia/Reoxygenation-Induced AIF Release Does Not Contribute to
Parthanatos
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation model and
cell death was detected and quantified as described earlier in Figure 9. PARP-1 inhibitor, 3ABA at 10 μM, 50 μM and 100 μM were added during both the hypoxia and the reoxygenation
phases. Data at 36 hours post-reperfusion are shown as mean ± SD and representative of at
least 3 independent experiments. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = nonsignificant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test.
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3.8 – CypD Ablation in Donor Hearts Attenuates IRI-Induced Allograft Injury
and Promotes Long-Term Graft Survival
Static cold (4°C) storage is the most commonly used strategy in donor organ
preservation [218, 219, 220]. Myocardial tissue is particularly sensitive to ischemia, and donor
heart preservation is limited to 4-6 hours in clinical transplantation [4, 5, 6, 7, 8, 9, 10, 12].
Our in vitro data strongly supported the role of CypD inhibition and ablation in protecting
endothelial cells from hypoxia/reoxygenation-induced necroptosis. We wanted to extend our
findings to a clinically relevant model of cardiac transplantation. To study the in vivo efficacy
of CypD ablation in promoting graft survival, donor hearts from WT and CypD-/- B6 mice were
subjected to ischemic storage at 4°C for 4 hours and then transplanted into BALB/c mice. Our
data show that ischemia aggravates graft rejection and significantly reduces graft survival time
compared to non-ischemic grafts (Figure 17A). Interestingly, CypD ablation in donor hearts
attenuates ischemia-induced rejection and promotes graft survival (Figure 17B).
Histomorphological evaluation of WT and CypD-/- allografts at 28 days posttransplantation indicated significant damage to the microvasculature, with neointima formation
and fibrosis in the WT allografts (Figure 18A&B). These changes indicated severe
inflammatory damage and were accompanied with T cell and monocyte/macrophage
infiltration into the graft as assessed by CD3 and CD68 staining (Figure 18C). Allograft injury
to the microvasculature, inflammatory damage and lymphocyte infiltration into the graft were
significantly decreased in the CypD-/- allografts (Figure 18D).
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Figure 17 – CypD Ablation Attenuates IRI-Induced Allograft Injury and Promotes LongTerm Graft Survival
Heart grafts from WT and CypD-/- B6 mice were subjected to ischemic storage at 4°C for 4
hours before being transplanted into BALB/c mice followed by anti-CD40L injection. Graft
survival was monitored twice a week. Cessation of beating was considered as rejection. (A)
Ischemia aggravates graft rejection and reduces graft survival time. n = 4; *p ≤ 0.05; Log-Rank
test. (B) CypD deficiency in donor hearts attenuates ischemia-aggravated graft rejection and
prolongs graft survival time. n = 4/group; *p ≤ 0.05; Log-Rank test.
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Figure 18 – CypD Ablation Attenuates IRI-Induced Allograft Injury, Inflammatory
Damage and Alloimmune Response
Heart grafts from WT and CypD-/- B6 mice were subjected to ischemic storage at 4°C for 4
hours before being transplanted into BALB/c mice as described in Figure 17. Recipient mice
(n = 4/group) were euthanized 28 days post-transplantation and the cardiac allografts were
isolated, fixed with 10% neutral buffered formalin and embedded in paraffin for sectioning.
The tissue sections were then stained with H&E, Verhoeff–Van Gieson Elastic Stain and CD3
& CD68 Immunohistochemistry. Nikon ECLIPSE E200 microscope was used to capture
images at 20X and 4X magnification. Allograft injury was evaluated and quantified based on
damage to microvasculature, neointima formation, fibrosis and lymphocytic infiltration
compared to naïve tissue by a pathologist in a blinded manner. The criteria used scored the
injury on a scale of 0-4 as follows – 0: no change, 1: 0-24% change, 2: 25-49% change, 3: 5074% change, and 4: >75% change. Representative slide images are shown. (A) Hematoxylin
& Eosin staining of tissue sections from cardiac grafts isolated from WT and CypD-/- mice,
indicating damage to the endothelium. (B) Elastic staining of tissue sections from cardiac grafts
isolated from WT and CypD-/- mice, indicating damage to the microvasculature. (C) CD3 and
CD68 Immunohistochemistry of tissue sections from cardiac grafts isolated from WT and
CypD-/- mice, indicating graft infiltration by T cells and monocytes/macrophages, respectively.
(D) Quantification of WT and CypD-/- cardiac graft injury in WT and CypD-/- mice, evaluating
arterial damage, neointima formation, fibrosis and lymphocytic infiltration. n = 3; ***p ≤
0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way ANOVA; Tukey’s
multiple comparisons test.
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Chapter 4
DISCUSSION
4.1 – Study Summary
A growing body of evidence indicates that necroptosis plays an important role in the
pathogenesis of numerous clinical conditions and diseases [102, 103, 104, 105, 106, 109, 110].
The pathological relevance of necroptosis in the context of organ transplantation is particularly
significant. Necroptosis is an inflammatory form of cell death that contributes to graft injury
and triggers alloimmunity, which adversely affects graft survival and function [102, 103, 104,
105, 109, 110]. Studies by our group have demonstrated the role of necroptosis in inducing
inflammation and tissue injury in donor heart and kidney grafts [103, 104]. We have previously
demonstrated that RIPK1 and RIPK3 contribute to necroptosis and that RIPK3 ablation
attenuates graft rejection [103, 104]. While the upstream pathways of necroptosis are wellestablished, the role of mitochondria and the downstream mechanisms involved remain
controversial [102, 106]. A recent study by our group demonstrated that the downstream
pathway of necroptosis involves CypD-mediated mPTP formation and that CypD-deficient
donor hearts exhibit prolonged survival [104].
In this study, we investigated the role of necroptosis in cell death induced by cold
hypoxia-reoxygenation injury, which modeled in vivo IRI. Our data indicate that necroptosis
plays a significant role in hypoxia/reoxygenation-induced cell death in endothelial cells,
indicating its relevance in IRI and organ transplantation. Inhibition of caspases prevents
hypoxia/reoxygenation-induced apoptosis but promotes necroptosis and significantly increases
overall cell death (Figure 9A&B). We were able to corroborate findings from our previous
81

study indicating the role of CypD in necroptosis using the in vitro cold hypoxia-reoxygenation
injury model. We found that CypD inhibition (and ablation) significantly attenuates
hypoxia/reoxygenation-induced necroptosis (Figure 11). We then extended our findings to a
clinically relevant model of cardiac transplantation. Donor hearts from WT and CypD-/- mice
were subjected to static cold storage (ischemic injury) followed by heterotopic transplantation
into BALB/c mice (reperfusion injury). We found that pre-transplant ischemia aggravates
cardiac allograft rejection and that CypD-/- cardiac allografts survive significantly longer than
WT cardiac allografts (Figures 17 and 18). Our in vitro and in vivo studies confirmed that
CypD plays an essential role in the necroptotic pathway and that inhibiting CypD confers
protection against IRI and attenuates alloimmunity.
Subsequently, we investigated the roles of various potential mediators downstream of
CypD-mediated mPTP formation. We first ruled out the roles of ROS (oxidative damage) and
the PGAM5-Drp1 axis (mitochondrial fragmentation) in hypoxia/reoxygenation-induced
necroptosis (Figure 10). We observed the translocation of AIF to the nucleus and AIF-mediated
DNA degradation into ~50 kbp fragments following cold hypoxia-reoxygenation injury
(Figures

14

and

15).

We

found

that

AIF

silencing

significantly

decreases

hypoxia/reoxygenation-induced necroptosis (Figure 13A). Since no known pharmacological
inhibitors of AIF exist, we confirmed our results by restricting AIF translocation to the nucleus
via CypA inhibition, since CypA is required for the translocation of AIF to the nucleus [148,
152, 153]. CypA inhibition also decreases hypoxia/reoxygenation-induced necroptosis (Figure
13B). We found that disrupting the upstream pathway of necroptosis via RIPK1 inhibition
prevents AIF translocation to the nucleus and DNA degradation into ~50 kbp fragments
(Figures 14 and 15). These findings suggest that AIF may be the downstream mediator in
necroptosis.
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4.2 – The Endothelium in Organ Transplantation
The endothelium is critical in maintaining the vascular homeostasis and constitutes the
first barrier between the recipient’s immune system and the allograft. Substantial injury to the
endothelium results in loss of vascular integrity and tone, increased vascular permeability and
intravascular thromboses, which disrupts blood flow, promotes inflammation and
alloimmunity and ultimately, contributes to graft injury and necrosis [65, 66, 67, 77, 90, 95,
96]. Endothelial cells are susceptible to the different forms of PCD induced by IRI [8, 10, 65,
66, 67, 77, 90, 103, 104]. Given the central role of the endothelium in initiating and promoting
the alloimmune response, preventing endothelial cell death is particularly important.

4.3 – Necroptosis in IRI and Organ Transplantation
IRI is an inevitable consequence of organ transplantation (Figure 1) with lifethreatening consequences in the immediate postoperative period, such as PGD. IRI has also
been shown to have deleterious long-term effects on graft survival and contributes to graft
rejection (Figure 3) [4, 8, 12]. Improvements in organ preservation processes and posttransplantation immunosuppressive protocols have not diminished the impact of IRI on graft
survival and function; therefore, current research efforts are focused on minimizing IRI itself.
IRI is associated with unregulated necrosis and various forms of PCD (Figures 2, 4 and 5). A
thorough understanding of the mechanisms involved in PCD can aid in the designing of
targeted therapies that disrupt IRI and promote graft survival [8, 12, 13, 18].
Historically, apoptosis was considered the sole form of PCD, with essential roles in
homeostasis, development and numerous disease processes, including IRI. However, evidence
now indicates that necrosis, which was previously regarded as an unregulated form of cell
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death, can occur in a regulated manner [102, 105, 154]. There are many different forms of
regulated necrosis (Figure 4) [101]. Amongst the different forms of regulated necrosis induced
by IRI, the best characterized and clinically relevant in the context of organ transplantation is
necroptosis [13, 102, 103, 104, 105, 109, 110, 154, 155, 156, 157, 158]. Necroptosis is a highly
inflammatory form of cell death that triggers robust alloimmune responses due to the release
of cDAMPs and cytosolic contents [102, 103, 104, 154, 155, 156, 157, 158]. Thus, inhibiting
IRI-induced necroptosis will minimize the loss of functional cells and limit the inflammatory
and alloimmune injuries in organ transplantation [102, 103, 104, 156, 157, 158].
In a recent study by our group, we showed that endothelial cells are susceptible to
TNFα-induced necroptosis [104]. Considering the role of endothelial dysfunction in
augmenting graft injury and promoting alloimmunity, we investigated the role of
hypoxia/reoxygenation-induced necroptosis in endothelial cells. Our findings indicate that
necroptosis plays a significant role in hypoxia/reoxygenation-induced endothelial cell death
and that the inhibition of caspases decreases apoptosis but increases necroptosis and overall
cell death (Figure 9A). To develop a better understanding of the necroptotic pathway, we
designed this study to investigate the putative mediators and downstream mechanisms
activated following the upstream signaling.

4.4 – Role of Mitochondria in Hypoxia/Reoxygenation-Induced Necroptosis
In necroptosis, the sequence of events downstream of the RIPK1/RIPK3 necrosome
formation and phosphorylation of MLKL is a subject of scientific controversy (Figure 5) [102,
104, 106]. Specifically, the evidence for the role of mitochondria in necroptosis is conflicting
[102, 104, 106]. While the majority of the studies support a role for mitochondria in
necroptosis, a few studies suggest that the mitochondria may be dispensable for this process
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[106]. This was best argued by Tait et al. who showed that widespread mitochondrial depletion
via mitophagy in SVEC and 3T3 cells did not disrupt necroptosis [128]. One proposed pathway
that does not involve the mitochondria implicates the translocation of oligomerized pMLKL
to the plasma membrane, followed by its rupture. Although inconclusive, evidence for this
pathway was presented by Cai et al. and Chen et al. using multiple cell types [133, 134].
The earliest studies investigating the downstream mechanisms of necroptosis indicated
a shift in metabolism leading to ROS production following necrosome translocation to the
mitochondria (Figure 5) [106]. In a study done by Lin et al. using MEFs, TNFα signaling
increased ROS levels and necroptosis and the use of the ROS scavenger, butylated
hydroxyanisole, efficiently blocked necroptosis following TNFα stimulation [115].
Furthermore, the ablation of critical necroptotic mediators, RIPK1, TRAF2 and FADD, led to
decreased ROS levels and resistance against TNFα-induced necroptosis. Vanlangenakker et al.
later demonstrated that the RIPK1/RIPK3-mediated ROS generation following TNFα
stimulation in L929 cells were mitochondrially derived [116]. These findings were
corroborated by Ardestani et al., who used two different cell lines, L929 and RAW 264.7, to
demonstrate the mitochondrial origin of ROS generated following TNFα stimulation [117].
The strongest evidence indicating the role of mitochondrial ROS in necroptosis was provided
by Davis et al., who showed the translocation of RIPK3 to the mitochondria following TNFα
stimulation and inhibition of necroptosis with the mitochondrial antioxidant MnSOD in
endothelial cells [122].
The earlier studies strongly implicating a role for mitochondrial ROS in necroptosis
were later disputed by findings from other studies, which indicated that ROS were not
'absolutely’ essential for necroptosis. He et al. suggested that the downstream mechanism of
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necroptosis may be cell-type specific [159]. While establishing the role of RIPK3, they showed
that ROS scavenging in HT-29 cells did not attenuate TNFα-induced necroptosis. This
observation was supported by a study by Temkin et al., which precluded the role of
antioxidants (ascorbic acid, glutathione and NAC) in rescuing THP-1 cells from TNFα-induced
necroptosis [120]. Hence, the role of ROS in mediating necroptosis requires further
investigation.
IRI is associated with significant production of ROS, including ROS generated
secondary to mitochondrial damage and ETC disruption (Figure 2) [13, 18]. We, therefore,
decided to investigate the role of ROS in hypoxia/reoxygenation-induced necroptosis. In our
study, treatment with the ROS scavengers, TEMPOL and NAC, did not result in a significant
reduction of hypoxia/reoxygenation-induced necroptosis (Figure 10 B&C). The use of the
mitochondria-specific

ROS

scavenger,

mito-TEMPOL,

also

did

not

inhibit

hypoxia/reoxygenation-induced necroptosis (Figure 10D). Although unexpected, our findings
are not entirely surprising. Endothelial cells have low-energy turnover and generate most of
their ATP molecules via anaerobic glycolysis [95, 160, 161, 162]. A significant mechanism of
ROS production following reperfusion injury is associated with ischemia-induced ETC
dysfunction. While speculative, it is possible that since the endothelial cells rely primarily on
anaerobic glycolysis, ROS production secondary to ETC dysfunction is minimal and, unlike
with other cell types, does not contribute to hypoxia/reoxygenation-induced necroptosis in
endothelial cells.
Another potential mediator of necroptosis involves the PGAM5-Drp1 axis (Figure 5).
According to a study by Wang et al., following its formation, the necrosome translocates to
the mitochondria and interacts with PGAM5. Activated PGAM5, in turn, activates Drp1 and
86

induces mitochondrial fragmentation. Data from this study indicate a direct interaction
between RIPK1/RIPK3 and PGAM5 indicated by coimmunoprecipitation assays.
Furthermore, Drp1 silencing and treatment with the PGAM5 inhibitor, MDivi-1, inhibited
TNFα-induced necroptosis [123]. These findings were later supported by Zhang et al., who
showed that Drp1 depletion in NRK-52E cells resisted TNFα-induced cell death [124]. Drp1
inhibition has also been shown to be protective against IRI and recommended as a novel
therapeutic strategy for cardioprotection [163].
The role of mitochondrial PGAM5-Drp1 axis has been disputed by recent studies by
several groups [128, 129, 130, 131]. These studies used PGAM5 and Drp1 silenced or deficient
MEFs and L929 cells and did not find a reduction in cell death following TNFα stimulation
[106, 131]. In our study, PGAM5-Drp1 axis inhibition in endothelial cells did not protect
against hypoxia/reoxygenation-induced cell death (Figure 10A) and ruled out mitochondrial
fragmentation as the mechanism responsible for cellular demise in hypoxia/reoxygenationinduced necroptosis. However, a recent study by Zhang et al. suggested that Drp1 modulates
CypD-mediated mPTP formation and mitochondrial ROS production [163]. It remains to be
established how this interaction relates to necroptosis.
We have previously shown that mitochondria critically participate in necroptosis and
that inhibition of CypD mediated mPTP formation attenuated necroptosis in endothelial cells
[104]. In this study, we ruled out the role of ROS and PGAM5-Drp1 axis in
hypoxia/reoxygenation-induced necroptosis and then investigated the role of CypD-mediated
mPTP formation in hypoxia/reoxygenation-induced necroptosis.

4.5 – Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells Involves
CypD-Mediated mPTP Formation
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The role of CypD-mediated mPTP formation in necroptosis has been the subject of
considerable study (Figures 2, 4, 5 and 7). In studies conducted by Baines et al., Nakagawa et
al., and Schinzel et al., CypD-mediated mPTP formation was shown to be involved in
necroptosis [125, 126, 127]. These studies indicated that CypD ablation provided resistance
against necroptosis induced by ROS-mediated oxidative damage and mitochondrial calcium
overload. In the setting of IRI, mPTP formation also provides a link to ROS production. While
ROS-mediated oxidative damage promotes CypD-mediated mPTP formation by sensitizing
mPTP to mitochondrial calcium, mPTP formation augments ROS production by contributing
towards ETC dysfunction and incomplete oxygen reduction [20]. This was confirmed in a
study by Roca and Ramakrishnan, which showed that TNFα-induced ROS production and
necroptosis in macrophages were both blocked by CypD inhibition [164].
As with the other proposed mitochondrial mediators, the role of mPTP formation in
necroptosis has also been questioned [106, 128]. The most compelling evidence against the
involvement of mPTP formation in necroptosis was presented in studies by Tait et al., and
Ch’en et al. [128, 165]. These studies showed that although RIPK1 and RIPK3 ablation
rescued caspase-8-deficient cells from necroptosis, CypD ablation did not. Linkermann et
al. also argued against the involvement of mPTP formation by showing that simultaneous
RIPK3 and CypD ablation provided greater protection against IRI-induced necroptosis than
separate RIPK3 and CypD depletions [132]. The findings from these studies suggested that the
proposed necroptotic pathway involving the upstream RIPK1/RIPK3/pMLKL and the
downstream CypD-mediated mPTP formation pathways were divergent.
Gan et al. from our group, however, confirmed that the protection conferred by CypD
ablation is not additive to that conferred by blocking the upstream signaling pathway of
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necroptosis via RIPK1 inhibition in endothelial cells [104]. Our group also showed that the
phosphorylation of MLKL, an established event in necroptosis, was suppressed by CypD
inhibition and ablation. These findings confirmed that CypD-mediated mPTP formation was
the downstream mechanism involved in TNFα-induced necroptosis in endothelial cells. In this
study, we found that hypoxia/reoxygenation-induced necroptosis in endothelial cells was
significantly reversed with CypD inhibition and ablation (Figure 11). Furthermore, the
protection conferred by CypD inhibition was not additive to that conferred by RIPK1
inhibition. We, therefore, concluded that hypoxia/reoxygenation-induced necroptosis in
endothelial cells is dependent on CypD-mediated mPTP formation.
While inconclusive, recent evidence also implicates CypD-mediated mPTP formation
in apoptosis (Figure 6). The earliest evidence supporting this position was presented in a study
by Murphy et al., who showed that the overexpression of the anti-apoptotic protein BCL-2
suppresses calcium-induced mPTP formation [166]. Later, Crompton et al. and Green et al.
reported that the use of the CypD inhibitor CsA blocked some forms of apoptosis [167, 168].
Most importantly, in its most current model, the OMM component of mPTP is formed by the
pro-apoptotic proteins BAX and BAD [138, 143]. However, most evidence associating CypDmediated mPTP formation to apoptosis is circumstantial and indirect. It is possible that the
ROS generated secondary to mPTP formation in the setting of cellular injury trigger apoptosis.
mPTP formation also dysregulates cytosolic calcium homeostasis, which can then activate
calpains and calcineurin [138, 169]. Calpain-mediated BID cleavage promotes OMM
permeabilization by BAX and BAK [170]. Similarly, calcineurin activates the pro-apoptotic
protein BAD, which then antagonizes the anti-apoptotic activities of BCL-2 and BCL-XL
[171]. Persistent mPTP formation also leads to mitochondrial swelling followed by OMM
rupture, which may facilitate the release of the pro-apoptotic mediators [13, 18, 20].
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In

order

to

exclude

the

role

of

CypD-mediated

mPTP

formation

in

hypoxia/reoxygenation-induced apoptosis within this study, we used the pan-caspase inhibitor
z-VAD-fmk in our in vitro cold hypoxia-reoxygenation injury model. The use of the pancaspase inhibitor also indicates that the DNA degradation in necroptosis is not mediated by
caspase-activated DNases (Figure 9A). In fact, our findings show that inhibition of caspases
promotes DNA degradation into ~50 kbp fragments. Hence, it is likely that CypD-mediated
mPTP formation leads to necroptosis without contributing to apoptosis.

4.6

–

Downstream

of

CypD-Mediated

Mitochondrial

Damage,

Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells Involves AIF
The scientific controversy involving the role of CypD-mediated mPTP formation in
necroptosis has diverted attention from investigating the precise downstream mechanisms
activated by its formation. As described earlier, mPTP augments ROS production, the role of
which was supported by the earlier studies investigating the downstream mechanisms of
necroptosis (Figure 2) [106, 115, 116, 117, 119, 119]. In this study, our findings suggested that
the

mitochondrial

ROS

generated

secondary

to

mPTP

did

not

contribute

to

hypoxia/reoxygenation-induced necroptosis since treatment with mito-TEMPOL did not
confer any protection (Figure 10D). More importantly, however, our findings suggested that
CypD-mediated mPTP formation was not dependent on ROS since the use of ROS scavengers,
unlike CypD inhibition, did not attenuate necroptosis. This finding supports a 'direct' link
between the upstream necroptotic pathway involving RIPK1/RIPK3/pMLKL and CypDmediated mPTP formation.
After excluding the role of ROS and caspases downstream of CypD-mediated mPTP
formation in hypoxia/reoxygenation-induced necroptosis, we investigated the role of AIF. The
90

dual and apparently paradoxical roles of AIF in cellular life and death can best be compared to
Cyt C. AIF has an essential survival role as a mitochondrial oxidoreductase involved in the
assembly and stabilization of the ETC components, Complex I and Complex III [147, 148,
150]. However, once released into the cytosol, it quickly translocates to the nucleus and
induces DNA degradation (Figure 8) [145, 146, 147, 148]. Since its discovery by Susin et al.
20 years ago, several studies have reported the involvement of AIF in various clinical
conditions and diseases [147, 148]. The role of AIF in IRI is well-established [147, 148, 172,
173, 174, 175, 176]. Soon after its discovery, Plesnila et al. and Kim et al. published studies
supporting a role for AIF in cerebral and myocardial IRI-induced cell death, respectively [174,
175]. Culmsee et al. later demonstrated that compared to WT mice, Hq mice displayed smaller
infarct volumes and significantly reduced neuronal death after transient cerebral artery
occlusion [176]. More recent studies have shown the role of AIF in non-ischemic pathological
conditions as well [145, 146, 147, 148, 172, 177, 178].
The mechanism regulating the processing and translocation of AIF to the nucleus is
complex and not fully understood. The release of AIF from the mitochondria involves two
essential steps: proteolytic cleavage yielding the truncated 'liberated' form of AIF and
permeabilization of mitochondria that enables its exit. While not completely established, it is
speculated that the cleavage of AIF to its liberated form is mediated by cysteine proteases such
as calpains and cathepsins (Figure 8) [147, 148]. Several studies, including one from the group
that discovered AIF, have shown that the dissipation of ΔΨm accompanies the release of AIF
from mitochondria [147, 148, 172]. These studies are supported by experiments in which
treatment with CsA blocks the release of AIF from the mitochondria suggesting that mPTP
may be the channel through which AIF is released into the cytosol [145, 177, 178].
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Our findings from this study clearly support a role for AIF in hypoxia/reoxygenationinduced necroptosis in endothelial cells. In cells undergoing necroptosis, translocation of AIF
to the nuclei (Figure 14) and DNA degradation into ~50 kbp fragments was observed (Figure
15). These changes were associated with the phosphorylation of MLKL, a crucial event in
necroptosis. Interruption of the upstream necroptotic pathway via RIPK1 inhibition reversed
these changes. Furthermore, AIF-silenced cells, like CypD-ablated cells, were resistant to
hypoxia/reoxygenation-induced necroptosis. Our findings, coupled with studies indicating a
role for mPTP in necroptosis and AIF release, indicate that hypoxia/reoxygenation-induced
necroptosis in endothelial cells involves the release of AIF from CypD-mediated mPTP
formation following RIPK1/RIPK3/pMLKL translocation to the mitochondria. While there is
considerable evidence supporting a role for mPTP in necroptosis and studies suggesting its role
in the release of AIF, our findings connecting the established upstream pathway of necroptosis
involving RIPK1/RIPK3/pMLKL to AIF release via CypD-mediated mPTP formation is novel.
Genomic stress leading to PARP-1 activation has been strongly implicated in various
diseases [149, 179]. In the setting of IRI, ROS-mediated oxidative damage to DNA and
subsequent activation of PARP-1 has been reported in various tissues, including the brain,
heart, intestine and retina [149, 179, 180, 181, 182]. PARP-1 activation causes ADP
ribosylation of 'damaged' chromatin, modulating its structure and facilitating its interaction
with DNA repair enzymes. However, if the DNA damage is severe, the excessive PAR
moieties in the nucleus translocate to the mitochondria and mediate AIF release, ultimately
leading to a form of cell death termed parthanatos (Figure 4) [147, 149].
In this study, neither treatment with the ROS scavengers nor PARP-1 inhibition
decreased hypoxia/reoxygenation-induced cell death (Figure 16). This finding indicated that
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the ROS-mediated DNA damage following cold hypoxia-reoxygenation injury, if present, was
not sufficiently severe to induce the accumulation of excessive PAR moieties in the nucleus.
The failure to attenuate cell death with direct inhibition of PARP-1 confirmed that the AIF
release following cold hypoxia-reoxygenation injury was unrelated to PARP-1 activation and
parthanatos. While targeting AIF to disrupt necroptosis is a promising prospect, it presents two
problems. Firstly, no pharmacological inhibition of AIF currently exists, and secondly, AIF
has an essential pro-survival role in cellular bioenergetics. The translocation of AIF to the
nucleus is facilitated by CypA and suppressed by HSP-70 [147, 148, 172]. As with the
silencing of AIF, CypA inhibition protected endothelial cells from hypoxia/reoxygenationinduced necroptosis. Our findings showed that CypA inhibition blocked AIF translocation to
the nucleus and DNA degradation into ~50 kbp fragments. CypA inhibition, therefore,
represents an effective therapeutic strategy to disrupt AIF-mediated necroptosis. Our findings
are supported by recent studies indicating a protective role for CypA inhibition in IRI [147,
148, 153, 172, 183].

4.7 – CypD Ablation Attenuates Cardiac Allograft Injury and Transplant
Rejection
CypD inhibition has been shown to protect against IRI and neurodegenerative
disorders. The protection conferred by pharmacological inhibition of CypD against IRI has
been confirmed with CypD ablation in every organ tested, including heart, kidneys, intestine
and liver [18, 137, 138, 141, 184, 185, 186, 187, 188, 189, 190, 191, 192]. Inhibition of CypDmediated mPTP formation underlies the cardioprotection elicited by the endogenous
phenomenon of ischemic conditioning and has been recommended as a potential therapeutic
target in the management of myocardial infarction [184, 185]. These studies strongly indicate
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that CypD-mediated mPTP formation can be used as an effective strategy in organ preservation
as well. More recently, Tran et al. have shown that mPTP formation promotes endothelial cell
immunogenicity in the setting of IRI that can be negated by CypD inhibition [193]. While their
study focuses on the role of mPTP formation in transplant immunity, it is plausible that the
increase in endothelial cell immunogenicity is the result of necroptotic cell death. Our group
has previously shown that interrupting necroptosis via RIPK3 ablation attenuates allograft
injury and transplant rejection in cardiac and renal transplantation models [103, 104]. CypD
deficiency in donor hearts conferred the same protection [104].
In this study, we extended our findings to a clinically relevant model of donor heart
preservation involving cold ischemic storage followed by transplantation. Our findings showed
that pre-transplant ischemia aggravates cardiac allograft rejection. Donor hearts subjected to
ischemia had shorter survival times compared to non-ischemic hearts (Figure 17A).
Interestingly, CypD deficiency in donor hearts attenuated graft rejection and promoted
allograft survival dramatically (Figure 17B).

4.8 – Therapeutic Strategies to Disrupt Necroptosis
Pharmacological and genetic inhibition of necroptosis has been shown to ameliorate
several diseases with an inflammatory component [102, 105, 194, 195, 196]. The first
pharmacological inhibitor investigated for use in clinical practice was Nec-1, an allosteric
inhibitor of RIPK1 [102, 197, 198]. However, limited half-life, poor pharmacokinetic
properties and off-target activity precluded its use [102, 197, 199, 200, 201, 202, 203].
Optimization of Nec-1 generated Nec-1s, which enhanced its specificity, but the poor
pharmacokinetic properties associated with Nec-1 persist and a clinical trial is yet to be
completed [102, 197, 200, 203]. The newer RIPK1 kinase inhibitors developed by
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GlaxoSmithKline, including GSK'963 and GSK'2982772, have shown efficacy against
necroptosis in human cells [204, 205, 206]. However, the results were not replicated in mouse
and rat cells, limiting explorations of their in vivo therapeutic value with animal disease models
[206]. RIPK3 kinase inhibitor GSK'872 and MLKL inhibitor necrosulfonamide have also been
developed, but in vivo data using animal models are lacking [206, 207, 208, 209, 210]. The
interconnected pathways involving the various forms of PCD and essential cellular functions
is a limiting factor in the use of all these drugs [197, 203, 206].
Since it was first discovered in 1972, the CypD inhibitor CsA has been crucial in
achieving improved survival rates in patients following organ transplantation [211, 212]. While
the current use of CsA in the post-transplantation setting is aimed at suppressing the immune
system by repressing the IL-2 -mediated activation of T cells, it is possible that the beneficial
effects of CsA in organ transplantation involves its inhibitory effect on CypD and prevention
of mPTP formation [104, 211, 212]. In fact, although the immunosuppressive capacity of CsA
is less potent than other immunosuppressive agents such as tacrolimus, mycophenolate-mofetil
and rapamycin, it provides greater protection against graft loss compared to these compounds
[211, 213, 214, 215, 216, 217]. As with several other studies, findings from this study have
shown that the use of CsA in organ transplantation results in a reduced inflammatory response
and significantly improved graft survival and function. Our study is unique because we have
provided evidence indicating that this is due to the reduction in cell death via the highly
inflammatory necroptotic death pathway. A more intriguing challenge with the use of CsA (or
alternative pharmacological agents) to block necroptosis in organ transplantation is its targeted
and sustained delivery to the donor organ [211].
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In this study, inhibiting AIF translocation to the nucleus provided a more significant
benefit than inhibiting CypD-mediated mPTP formation with CsA. This might be due to the
presence of an AIF splice-variant located outside the mitochondria that is equally capable of
translocating to the nucleus and inducing DNA degradation as the mitochondrial AIF [147,
148]. Inhibition of AIF translocation targets both the mitochondrial and the extramitochondrial AIF, while the use of CsA prevents only the mitochondrial AIF from
translocating to the nucleus. Although more extensive testing needs to be done, our data explain
why Hq mice show resistance against IRI [147, 148, 152, 153, 172, 173, 174, 175, 176]. Since
AIF deficiency is associated with severe adverse effects, a better approach would be inhibition
of AIF translocation to the nucleus with the use of pharmacological agents such as Alisporivir.
Inhibition of AIF translocation may promote graft survival and attenuate alloimmunity by
inhibiting necroptosis while preserving the vital functions of AIF. As such, it represents a
potent therapeutic strategy in organ transplantation.
More recently, research investigating better organ preservation strategies have gained
a lot of attention [218, 219]. This includes the development of perfusion systems and the
‘engineering’ of organ preservation solutions to enhance the functional preservation of donor
organs [218, 219, 220]. Our in vitro data from this study showed that combined intervention
strategies during the hypoxia and reperfusion phases conferred greater protection than
intervention at any one stage. For this study, our in vivo experiments used the current model of
organ preservation involving static cold storage. It would be interesting to evaluate the efficacy
of CsA and Alisporivir in preserving graft viability when used as pharmacological additives in
organ preservation solutions used in perfusion pumps.

4.9 – Future Directions
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Our in vitro data shows the role of AIF in inducing necroptosis in endothelial cells
following cold hypoxia-reoxygenation injury. We are currently studying the role of AIF in in
vivo cardiac transplantation models using endothelium-specific AIF knockout mice generated
by Cre-LoxP recombinase system. We plan on investigating the role of AIF in inducing
necroptosis in other cell types such as renal tubular epithelial cells and believe that evaluating
cellular function following IRI is as important as evaluating cellular survival. In addition to
preserving cellular survival, it would be worthwhile investigating the role of the potential
therapeutic strategies in maintaining cellular function as well. This is important because organ
function is ultimately dependent on the integrated activities of its cells. Finally, we would like
to investigate the most suitable delivery and administration methods of the identified
pharmacological agents.

4.10 – Limitations
As with all in vitro experiments, a limitation of this study is that the in vitro cold
hypoxia-reoxygenation injury model used may not accurately represent the in vivo and clinical
conditions. For the in vitro cold hypoxia phase, anaerobic GENbags were used. The GENbags
use a chemical generator sachet to induce hypoxia. Although the results of the in vitro cold
hypoxia-reoxygenation injury were repeated with hypoxia induction in the Hypoxystation, the
results may not reflect physiological hypoxia. The GENbags also generate heat in the first 3060 minutes of the chemical reaction that induces hypoxia while the Hypoxystation can only be
set as low as 10°C, which does not reflect clinical conditions involved in organ transplantation.
In vitro experiments using a single cell-type, as is the case with this study, also do not take into
account the complex physiological and pathological cellular responses triggered by the cell’s
external environment. The cells may also react differently in in vivo and clinical settings
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depending on their interaction with leukocytes. Furthermore, the pathways involved in one
cell-type may not be activated/involved in other cell types. In this study, endothelial cells were
used to study the effects of IRI in the context of organ transplantation. Endothelial cells
represent only one component of IRI. They are also relatively resistant to hypoxia due to lowenergy turnover compared to cardiomyocytes (cardiac transplantation) or kidney tubular
epithelial cells (renal transplantation). Finally, the concentration of the proinflammatory
cytokines used in the in vitro settings may not be reflective of their physiological levels. In this
study, these problems were addressed by repeating in vivo experiments involving a clinically
relevant model cardiac transplantation.
To study the various pathways involved in necroptosis, several drugs were used. The
drugs used may have off-target effects and may influence other pathways involved. The use of
the drugs studied in the in vitro as well as in vivo studies may not be clinically applicable and
may have toxic effects at the concentrations used. This study did not address adverse effects
related to drug concentrations. This is particularly true for Alisporivir, which was discontinued
due to severe adverse effects (e.g., pancreatitis) following late stage clinical development as a
combination therapy for the treatment of HCV infection [221, 222]. Both CsA and Alisporivir
are cyclophilin-binding molecules and may bind non-specifically to other cyclophilins [104,
147, 148, 211, 212]. This problem was addressed by using gene knock-out and siRNA
interference silencing. However, these techniques may not be truly effective due to substantial
genetic variability, and siRNA interference silencing is limited to a few days. These problems
may be overcome by the use of shRNA interference silencing and CRIPSPR/Cas9 genome
editing.
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While data from this study indicate that AIF-silencing in endothelial cells confers
protection against hypoxia/reoxygenation-induced necroptosis, AIF is a physiologically vital
molecule essential in cellular bioenergetics, and its inhibition in cells with high-energy
turnover such as cardiomyocytes (cardiac transplantation) or kidney tubular epithelial cells
(renal transplantation) may exacerbate graft injury [147, 148]. A potential strategy may be to
inhibit AIF translocation to the nucleus rather than its inhibition. A therapeutic strategy aimed
at preventing AIF translocation globally in the context of organ transplantation is yet to be
designed.

4.11 – Conclusion and Study Significance
In this study, we corroborated findings from our previous study and presented evidence
indicating that targeting CypD-mediated mPTP formation presents a comprehensive
therapeutic strategy in organ transplantation [104]. We showed the role of CypD-mediated
mPTP formation in necroptosis using in vitro and in vivo experiments and investigated the
putative mechanisms activated downstream of mPTP formation. Our findings established the
role of AIF in necroptosis in endothelial cells and indicated that targeting AIF translocation
yields even greater protection than targeting CypD-mediated mPTP formation in organ
transplantation.
It is important to note that while the role of IRI-induced necroptosis in organ
transplantation is well-established, the development of clinically applicable pharmacological
agents in disrupting it represents a significant obstacle [102, 104, 202, 203, 206]. The ‘ideal’
pharmacological inhibitor will disrupt necroptosis without perturbing the vital pro-survival
physiological functions of the mediators involved. The goal of this study was to identify and
develop a better understanding of the downstream mechanisms of IRI-induced necroptosis. We
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believe that this will enable the generation of therapeutic strategies aimed at mitigating IRI and
the subsequent inflammatory and alloimmune responses, ultimately promoting graft survival
and function. Furthermore, the use of these pharmacological agents during donor organ storage
will enhance the functional preservation of organs and enable the use of marginal donors,
thereby addressing donor organ shortage.
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